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Integral to the success of surveillance programs is the quality of the measurement 
systems used to collect data. However, the performance of the measurement systems used to 
evaluate antimicrobial resistance and antimicrobial use is poorly defined. This thesis, therefore, 
examines the quality of evidence arising from the phenotypic assays and questionnaires used in 
the surveillance of animals.  
The performance of disc diffusion was evaluated to determine its fitness-of-purpose as 
a source of data for clinical decision-making and surveillance. Zone diameter and minimum 
inhibitory concentration values obtained from the first Australia-wide prevalence studies of 
clinical Escherichia coli and Staphylococcus pseudintermedius were used to estimate the 
accuracy of disc diffusion relative to broth microdilution. Conventional measures of test 
accuracy were described, including diagnostic sensitivity, specificity, and area-under-the-
receiver-operating characteristic (ROC) analysis. For most antimicrobials evaluated, disc 
diffusion was accurate at predicting the resistance of clinical E. coli and S. pseudintermedius 
that could otherwise be determined by broth microdilution. The assay performed strongly for 
ciprofloxacin and ceftiofur, and less favourably for amoxicillin-clavulanic acid, cephalothin, 
and cefoxitin. For S. pseudintermedius and oxacillin, the accuracy of broth microdilution was 
moderately better than disc diffusion relative to mecA real-time PCR. The precision of disc 
diffusion was investigated in a test-retest study using a linear mixed-model to estimate intra- 
and inter-laboratory agreement. Agreement was measured as repeatability (r) and 
reproducibility (R). The precision of disc diffusion was generally satisfactory for most 
antimicrobial agents, including ceftiofur (r=4.9mm, R=5.8mm) and gentamicin (r=4.9mm, 
R=5.4mm). However, the extent of variation in ampicillin (r=4.6mm, R=6.5mm) and 
trimethoprim-sulfamethoxazole (r=6.6mm, R=7.2mm) was of some concern. 
vi 
 
The management of antimicrobial resistance is aided by the collection of data on the use 
of antimicrobial agents via questionnaires or other survey tools. In this thesis, the Australian 
beef feedlot sector was used as a case study to examine a common survey method in which 
multi-stakeholder engagement is expected, often leading to methodological constraints in 
survey design. Here, a mailed questionnaire was used to obtain information on antimicrobial 
use in beef feedlots. The response rate was 16.1%. For those responding to the survey, the use 
of antimicrobials was found to be appropriate for the purpose indicated, and there was a strong 
preference for drugs of low importance to human health. While the low response rate dictates 
that inferences could only be weakly extended to the broader beef feedlot population, the data 
was of value in informing the development of antimicrobial stewardship guidelines and acted 
as a staging position for further research into antimicrobial use in other animal sectors. 
However, more reliable methods of survey delivery should be considered for the on-going 
collection of antimicrobial use data at the farm-level. 
Overall, this thesis concludes that for E. coli and S. pseudintermedius, susceptibility 
data from disc diffusion or broth microdilution generated in veterinary laboratories can 
contribute to national surveillance programs. This information, coupled with data from surveys 
of antimicrobial use at the farm-level, will be of substantial benefit to efforts aimed at managing 
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The research areas presented in this thesis contributed to a national multi-institution 
collaboration which examined the phenotypic and genetic diversity of bacterial pathogens of 
importance to animals and evaluated the measurement systems used to generate data for 
surveillance programs. Participating organisations included The University of Adelaide, The 
University of Sydney, Murdoch University, the Australian Government Department of 
Agriculture and Water Resources, and the New South Wales Department of Primary Industries. 
From January 2013 to January 2014, veterinary diagnostic laboratories (n=22) in Australia 
contributed Escherichia coli and coagulase-positive staphylococci bacterial isolates from 
clinical cases to The University of Adelaide reference laboratory. Isolates underwent 
phenotypic, genotypic, and molecular testing at multiple institutions.  
The quality of information derived from surveillance activities is dependent on the 
validity and reliability of the measurement tools used to collect information. High-quality data 
is necessary to implement strategies that manage antimicrobial resistance in animal populations. 
Hence, the research areas in this thesis focussed on three questions regarding the quality of the 
measurement systems used to generate data for surveillance programs:  
1. Are antimicrobial susceptibility data generated from the disc diffusion assay sufficiently 
accurate for inclusion in national surveillance programs for animals? (Chapters 2 and 3) 
2. How precise is disc diffusion when used in veterinary laboratories? (Chapter 4). 
3. How well do stakeholder-driven questionnaires perform when used to collect farm-level 
antimicrobial use data? (Chapter 5). 
A review of national surveillance programs and previous research into antimicrobial 
resistance and antimicrobial use in animals, along with a discussion on gaps in our collective 
knowledge is presented in Chapter 1. Chapters 2-5 present the objectives, methods, results, and 
discussion for each research area, while a detailed discussion, further research directions, and 















Antimicrobial resistance is a phenomenon that reveals the fragile interdependence 
between people, animals, and the environment; where overuse and misuse of these compounds 
have led to the rapid evolution and dissemination of antimicrobial resistance in bacterial 
populations (United Nations 2016; WHO 2015). Challenges associated with containing 
antimicrobial resistance are multidimensional. Of greatest concern are highly evolved 
mechanisms for the dispersal of resistance elements and genetic diversity in factors which 
rapidly select for resistance (Laxminarayan et al. 2013). Varying levels of awareness of 
antimicrobial resistance among medical professionals (Fletcher-Lartey et al. 2016; Labricciosa 
et al. 2018), veterinarians (Hardefeldt et al. 2017; Smith et al. 2018), and the community is a 
major barrier to changing behaviours and reducing use. Furthermore, deficiencies in data 
obtained by national surveillance programs impede our ability to mount an effective response 
to antimicrobial resistance and the over-consumption of antimicrobial agents. Consequently, 
there is a strong international consensus that integrated surveillance of people, animals, and the 
environment is essential if we are to fully comprehend the challenges associated with 
antimicrobial resistance (O'Neil 2016; OIE 2015b; WHO 2015). 
This literature review introduces the central theme of this thesis – the quality of evidence 
arising from the measurement systems used to understand and manage antimicrobial resistance. 
Specifically, the diagnostic tests used to measure bacterial resistance, and the survey methods 
used to collect antimicrobial usage data at the farm-level. This literature review provides an 
overview of the surveillance of resistance in bacterial populations derived from animals; the 
antimicrobial susceptibility tests used to determine resistance; the methods for evaluating 
diagnostic test validity and precision; and the collection of antimicrobial usage data for 





Surveillance for antimicrobial resistance in the microbiota of animals 
Epidemiologists are careful to distinguish between the terms ‘surveillance’ and 
‘monitoring’; however, in broader scientific usage, these terms are often synonymous despite 
differences in well-recognised definitions. Where surveillance is recognised as the systematic, 
on-going collection, analysis, interpretation, and dissemination of data to inform decision-
making, stimulate action, and evaluate risk mitigation activities (Hoinville et al. 2013; Thacker, 
Qualters & Lee 2012; WHO 2015); monitoring occurs without a pre-defined risk mitigation 
plan or defined threshold level for intervention (Hoinville et al. 2013; Salman 2003). 
Surveillance can be categorised into five different purposes: (i) demonstration of freedom from 
disease, (ii) early detection of disease, (iii) prevalence of disease in a population, (iv) 
monitoring change in disease in a population over time, and (v) detection of cases to control 
disease (Dohoo, Martin & Stryhn 2009; Hoinville 2011). For antimicrobial resistance, the role 
of surveillance is to enhance our understanding of the epidemiology and risk factors which 
influence emergence and spread, and with this information, implement, and evaluate 
interventions which reduce the burden of resistance (WHO 2013). 
Table 1 demonstrates a range of antimicrobial resistance surveillance activities which 
may fit within the five purposes of surveillance. From this table, comparisons can be made 
between each of the surveillance purposes (columns) and the epidemiological considerations 
(rows) required to design an effective surveillance program. For instance, the epidemiologic 
considerations necessary for the design of a surveillance activity to detect emerging resistance 
in a bacterial population are different from the design considerations for an activity which 
measures trends in resistance over time. In the former scenario, resistance is unknown or absent 
from a population, and the sampling strategy and sample size will be markedly different from 
the latter scenario where resistance is already well-characterised. It is clear from Table 1 that 
most national surveillance programs are in essence monitoring programs which have evolved 
to adopt elements of surveillance over time (McEwen, S, Aarestrup & Jordan 2006). 
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Table 1. Surveillance and epidemiologic characteristics of animal-focused antimicrobial resistance surveillance related to the five purposes of 
surveillance programs adapted from the WHO Guidance on the Integrated Surveillance of Antimicrobial Resistance in Foodborne Bacteria: 
Application of One-Health Approach (2017b) and the Animal Health Surveillance Terminology Report from the International Conference on 
Animal Health Surveillance (2011). 
 








Monitoring change Case detection 
Surveillance characteristics: 
Political context 













Public health information, 
risk analysis, design 
interventions, national 
database, measure success 
of interventions 
Public health information, 
risk analyses, design 
interventions, guidance 
for prescribers, national 
database 
Public health information, 
risk analyses, design 
interventions, guidance 
for prescribers, national 
database 
 
Compare prevalence over 




for prescribers, national 
database 
Determine interventions 





Demonstrate that a host 
population is free of a 
specified resistance gene 
for certain bacterial/host 
species  
Detect emerging 
resistance in a bacterial 
species to trigger actions  
 
Estimate prevalence and 
spatial distribution of 
resistance in a bacterial 
species/ host population 
at a point in time  
 
Analyse changes in 
prevalence/ incidence of 
AMR in bacterial species/ 
host population over time 
Find cases of AMR in 
bacterial species from a 
host population to 
intervene  
Expected outcome of 
surveillance activity 
(and trigger level(s)) 
Probability of freedom of 
specified AMR in 
bacteria from host 
population  
 
Identify new resistance 
genes (may move to case 
detection if want to 
contain/ prevent transfer 
of resistance) 
 
Establish the prevalence 
of AMR in bacteria from 
host population.  
Establish trends in the 
prevalence of AMR in 
bacteria from host 
population.  
Identification of units of 
interest within host 
population (e.g., farm or 





Based on political 
outcomes and risk to 
human health. 
Restrictions on certain 
antimicrobial classes in 
host population 
 
Based on political 
outcomes and risk to 
human health. 
Restrictions on certain 
antimicrobial classes in 
host population 
Restrictions on certain 
antimicrobial classes in 
host population. Methods 
to prevent food 
contamination  
Restrictions on certain 
antimicrobial classes in 
host population. Methods 
to prevent food 
contamination 
Restrictions on certain 
antimicrobials in host 
population, restrictions on 
trade of animals, methods 
to prevent contamination 
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Monitoring change Case detection 
 
Epidemiological characteristics: 
Context of surveillance 
purpose 
Record free status from 
specified AMR genes 
Detect novel or emerging 
AMR genes 
 
Obtain AMR point 
prevalence data – 
phenotypic and/or 
genotypic data 
Monitor trends in AMR in 
a population over time 
Detect specified AMR 
genes to implement 
containment measures 
AMR status Absent Absent Present Present Present 
Scope of surveillance 
activity 
 
Ad hoc or continuous. 
Could be part of a 
portfolio of surveillance 
activities looking at one 
or more hazards. May be 
a single surveillance 
activity  
 
Ad hoc or continuous. 
Could be part of a 
portfolio of surveillance 
activities looking at one 
or more hazards. May be 
a single surveillance 
activity 
Ad hoc or one-off. Could 
be part of a portfolio of 
surveillance activities 
looking at one or more 
hazards 
Continuous. Part of a 
portfolio of surveillance 
activities looking at one 
or more hazards 
Continuous. Part of a 
network of surveillance 
activities to control 
hazard 




























Host population stream 
 
Diseased – clinical 
Healthy – farm, abattoir 
Diseased – clinical 
Healthy – farm, abattoir, 
retail 
Healthy – farm, abattoir, 
retail 
Healthy – farm 
Diseased – clinical 
Sampling strategy (for 


















Purposive/ targeted  
Sample size coverage 
required to meet 
objective 
Medium (for rare 
occurrence) 
Medium-high (for rare 
occurrence) 
Low-medium (for higher 
prevalence) 




Origin of data 
Active 
Passive (lab data) 
 
Active 
Passive (lab data) 
Active 
Active 
Passive (lab data) 
Active 
Sampling method 
Bacterium or pooled 
sampling 




Bacterium or pooled 
sampling 
 
Bacterium or pooled 
sampling 

















Lab test confirmed: 
Phenotypic 
Genotypic (PCR, WGS),  
ECOFF 
Lab test confirmed: 
Phenotypic 
Genotypic (PCR, WGS),  
ECOFF 
Lab test confirmed: 
Phenotypic 
ECOFF 
Lab test confirmed: 
Phenotypic 
ECOFF 
Lab test confirmed: 
Phenotypic 














(CRE), colistin (mcr-1) 
and vancomycin-resistant 
(VRE) E. coli from 
livestock will be desirable 
Fluoroquinolone 
resistance in food 
animals; ESBLs in 
salmonella from food 
animals in Australia; 




Prevalence of AMR in 
Salmonella and E. coli 
from cattle in Australia in 
2015 (Barlow et al. 
2015); poultry (Barton & 
Wilkins 2001) (Australian 
Chicken Meat Federation 
2018); pigs (Kidsley et al. 
2018) 
National surveillance 
reporting prevalence of 
AMR in E. coli from pigs 
in Denmark since 1995 
(DANMAP 2017); 
Canada since 1997 
(Government of Canada 
2017) 
Methicillin-resistant 
Staphylococcus aureus in 
animals (Jordan, D. et al. 
2011; Sahibzada et al. 




Heidelberg in poultry in 
Canada (Dutil et al. 2010) 
 
AMR, antimicrobial resistance; ECOFF, epidemiological cut-off value; PCR, polymerase-chain-reaction; WGS, whole-genome sequencing 
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Over 20 countries have national antimicrobial surveillance programs which collect data 
on bacteria from people, animals, and food products. In most countries, national surveillance is 
focussed on pathogenic bacteria from people and zoonotic and commensal bacteria from 
healthy food animals and retail meat products. Bacteria from food animals and retail meat 
products of most interest are Salmonella spp., Campylobacter spp., Escherichia coli, and 
Enterococcus spp. These bacteria are included as they are thought to play a role in the transfer 
of genetic resistance elements to humans (OIE 2015b; WHO 2001). Countries without national 
surveillance programs, Australia included, have conducted small studies of limited time 
coverage to assess antimicrobial resistance in bacteria from food animals and retail meat 
products (Australian Chicken Meat Federation 2018; Barton & Wilkins 2001; Jordan, D 2003). 
Noticeably absent from most national surveillance programs is information on pathogenic 
bacteria from animals, with just a few countries, such as Denmark (DANMAP 2017), Germany 
(GERM-VET 2018), Norway (NORM/NORM-VET 2017), Sweden (Swedres-Svarm 2017), 
and France (RESAPTH 2017), monitoring some pathogenic bacteria from animals. The lack of 
data about pathogens represents a major knowledge gap regarding the prevalence of 
antimicrobial resistance in animals. A concerted effort is needed to obtain data on antimicrobial 
resistance in animal pathogens if we are to advance our understanding of the health risks posed 
to animals, people, and the environment (Barber, Miller & McNamara 2003; European Union 
2013; Guardabassi, Schwarz & Lloyd 2004). 
A lack of standardisation in national surveillance programs is a significant challenge for 
coordinated action on antimicrobial resistance (Bax et al. 2001; Fluit et al. 2006; Shaban et al. 
2014; White et al. 2001; WHO 2017a). The absence of standardisation, particularly in sampling 
procedures and laboratory testing methodologies, is a barrier to data-sharing and comparability 
of resistance levels between countries (WHO 2013). At present, the only comparable 
antimicrobial resistance surveillance data are from programs conducted in EU-member states, 
the United States, and Canada (WHO 2013). The OIE (2016) and WHO (2017b) have published 
guidelines on the standardisation of antimicrobial surveillance, and the European Parliament 
8 
has enacted legislation to impose standardisation of antimicrobial resistance surveillance in all 
member states (European Union 2013). However, countries may have different objectives for 
surveillance, access to funding, legislation, infrastructure, and farm practices which will affect 
the design, and standardisation, of surveillance activities and therefore the ability to compare 
surveillance data. 
Surveillance objectives should be specific, measurable, and time-dependent and form 
the basis for planning and evaluation. The broadly agreed objectives for most surveillance 
programs of antimicrobial resistance include the (i) determination of resistance in a population, 
(ii) monitoring changes in resistance, (iii) detection of new mechanisms of resistance, (iv) 
investigation of the evolution of resistance, (v) determination of antimicrobial use patterns, and 
(vi) development and monitoring of interventions, (Franklin et al. 2001; OIE 2015b; Silley, 
Simjee & Schwarz 2012; WHO 2017b). For the most part, the objectives listed above are 
comparable to the purposes of surveillance outlined in Table 1, specifically the early detection 
of resistance, prevalence of resistance in populations, and monitoring change over time. 
However, for many national surveillance programs, the program objectives are often criticised 
for lacking clarity and relevance for animal populations (Jordan, D 2003; Lewis 2002). Poorly 
defined objectives in surveillance programs can lead to weak study design and impact on the 
quality and comparability of data outputs (Fluit et al. 2006; Franklin et al. 2001). 
Central to surveillance is the collection of objective and robust data, which can be 
achieved by a well-designed sampling strategy and the use of accurate and reliable 
measurement systems. Here, sampling is addressed. The sampling strategy should have two 
essential features: population representativeness and adequate sample size. Representativeness 
ensures the sample subset is, as much as possible, an accurate and unbiased reflection of the 
population from which the sample group is drawn; while a statistically appropriate sample size 
results in valid data outputs (Dohoo, Martin & Stryhn 2009; Franklin et al. 2001; WHO 2013). 
Flawed study design can result in weak data and inferior decision-making (Rempel, Pitout & 
Laupland 2011). Balancing the cost of sampling and the usefulness of the data is a considerable 
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challenge, especially in resource-challenged settings. Under-resourcing constrains the number 
of samples collected, sites visited (e.g., farms, abattoirs) and regularity of sample collection. 
Notwithstanding limitations in sampling, data outputs can still be useful, although they may be 
insufficient to address the objectives of a national surveillance program. 
Where representativeness in sampling is unachievable, as may be the case for certain 
surveillance activities in animal populations, risk-based sampling can be an efficient and 
resource-saving approach. This is particularly so for demonstrating freedom from disease or 
absence of infection (e.g., the absence of certain multi-drug resistant genes in bacteria from a 
food animal species). Risk-based sampling has been described as an approach whereby the 
sampling strategy applied to different strata in a population is based on the probability of 
infection (or carriage of resistance genes) in that strata (Cameron, AR 2012). For example, 
cattle reared in an extensive grazing system will likely have a lower risk of acquiring and 
disseminating resistance genes compared to cattle kept in a feedlot where infectious diseases 
and exposure to antimicrobial agents may be high. Therefore, the sampling strategy in 
extensively grazed cattle and feedlot cattle will be different based on their perceived level of 
risk of exposure to antimicrobial agents, selection pressure in bacterial populations, and 
carriage of resistant genes. 
Sampling design is often considered the most common source of systematic error (bias) 
in population measurements, yet it has historically received scant consideration when designing 
antimicrobial resistance surveillance activities (Dunlop et al. 1999; Jordan, D 2003). 
Inappropriate sampling occurs when it is incorrectly assumed that an event of interest (e.g., 
occurrence of resistant bacteria) is randomly distributed within the population of interest 
(Dohoo, Martin & Stryhn 2009). The non-random distribution of infectious agents is known as 
clustering. While it generally holds that the health status from animals within herds are more 
alike than the health status of animals from separate herds, several studies have also reported 
on clustering of resistant bacteria within faecal samples derived from individual animals and 
groups of animals from the same herd (Benedict et al. 2015; Dunlop et al. 1999; Humphry et 
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al. 2018). Thus, clustering can occur at multiple ‘levels’. Most national antimicrobial resistance 
surveillance programs implicitly assume homogeneity in bacterial populations at the farm-level 
and define the epidemiological unit of interest as a single bacterial isolate per farm. However, 
this approach ignores the phenomenon of clustering and will reduce the likelihood of 
identifying low-level or emerging bacterial resistance (Dunlop et al. 1999; Humphry et al. 2018; 
Persoons et al. 2011; Vieira et al. 2008).  
By assuming homogeneity at the farm-level, most national programs utilise standard 
sample size calculations to determine the number of bacteria required to evaluate resistance 
(Caprioli et al. 2000; Davison, Low & Woolhouse 2000; European Food Safety Authority 
2012). This assumption underestimates the sample size required for any given level of accuracy 
when clustering is present, and with this approach, it may not be possible to obtain an accurate 
assessment of the prevalence of antimicrobial resistance in a bacterial population derived from 
an animal species (Jordan, D 2003; Persoons et al. 2011; Shaban et al. 2014). Estimates of the 
prevalence of antimicrobial resistance from food animals could be less biased if the sample size 
was increased or the sampling unit was based on a pooled sample at the farm-level where 
clustering could be accounted. Techniques described by Dunlop et al. (1999), Wagner et al. 
(2002), Benedict et al. (2013), and Humphry et al. (2018) demonstrate the suitability of pooled 
faecal sampling in estimating the low-level prevalence of antimicrobial resistance in bacteria 
from animals. Coupled with affordable and reliable high-throughput laboratory testing, pooled 
sampling at the farm-level could overcome current deficiencies in the reporting of prevalence 
of resistance in food animals. Examination of ways to increase the sample size by using pooled 
faecal sampling and high-throughput laboratory testing was an original objective of this thesis; 
however, at the time of completion of the research phase, suitable protocols for exploiting the 
robotic technology at the Murdoch University Antimicrobial Resistance and Infectious Diseases 
(AMRID) Research Laboratory were still under development. 
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Antimicrobial susceptibility data which routinely accumulates in veterinary diagnostic 
laboratories could be used to enhance the current surveillance effort in animals. The collection 
of clinical data from laboratories is a form of passive surveillance (Dohoo, Martin & Stryhn 
2009; Thrusfield 2007). The strength of passive surveillance lies in its low cost and potential to 
identify emerging or rare resistance in bacterial pathogens, an objective of all existing national 
surveillance programs (Mather et al. 2016). However, passive surveillance is not without bias, 
since such data is typically derived from clinically unwell individuals, and there is a reliance 
on veterinarians (and consenting owners) to submit samples for investigation. For veterinary 
laboratories to be a reliable data source, a high level of confidence is needed in the performance 
of the phenotypic assays used in these laboratories. Specifically, the assays must be accurate 
and reliable within- and between-laboratories (Bax et al. 2001). 
 
Antimicrobial susceptibility assays 
In clinical settings, phenotypic antimicrobial susceptibility testing is used to determine 
the susceptibility of a bacterial isolate to an antimicrobial agent as an aid to therapeutic 
decision-making. While in surveillance, the use of phenotypic assays is different. Here, the 
assays are used to gather temporal and spatial data to aid the design of policies and 
interventions. 
The two most common phenotypic assays used in veterinary laboratories are broth 
microdilution and disc diffusion. Broth microdilution is the reference standard to which all other 
phenotypic assays are compared (ISO 2006), and is preferred for national surveillance as it 
generates quantitative data based on the minimum inhibitory concentration (MIC) (OIE 2018b). 
However, disc diffusion, which measures the zone of inhibition around an antimicrobial agent-
infused disc on agar, is commonly used in veterinary laboratories. This is because disc diffusion 
is affordable, customisable for a range of bacteria and antimicrobial agents, and requires 
minimal investment in equipment compared to broth microdilution. Indeed, a recent survey of 
American veterinary laboratories reported 71% of respondents performed disc diffusion 
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(Dargatz, Erdman & Harris 2017), while in Australia, all veterinary laboratories reported using 
disc diffusion to evaluate antimicrobial susceptibility (Hardefeldt et al. 2018).  
Bacterial isolates are usually described as being “susceptible”, “intermediate”, or 
“resistant” to an antimicrobial agent when the interpretative criteria, known as clinical 
breakpoints, are applied. Clinical breakpoints are used to determine an isolate’s susceptibility 
to the antimicrobial agents tested and to select the most suitable therapeutic agent. The clinical 
interpretation of disc diffusion results is considered comparable to those from broth 
microdilution, providing international standards for performing the assay such as those published 
by the Clinical and Laboratory Standards Institute (CLSI) or EUCAST are observed (Lestari et 
al. 2008; Matuschek, Brown & Kahlmeter 2014; Turnidge & Paterson 2007). Clinical 
breakpoints are determined by expert committees which consider MIC distributions, 
pharmacokinetics/ pharmacodynamics of the antimicrobial agent, and clinical outcomes 
(Turnidge & Paterson 2007). However, there are few clinical breakpoints specific to veterinary 
isolates/ drug combinations. Over-reliance on human breakpoints has led to challenges with the 
clinical interpretation of veterinary bacterial pathogens. If human breakpoints are inappropriate 
for a veterinary bacteria/ antimicrobial combination, the test result will be of limited value to 
the clinician. Unsuitable breakpoints can lead to inappropriate selection of antimicrobial agents 
and potentially select for resistance (Toutain et al. 2017).  
When setting clinical breakpoints for veterinary medicine, several issues need to be 
considered. Namely, antimicrobial agents may be administered to multiple animal species by 
various routes, dose rates, and using formulations with short-acting or long-acting durations of 
action. Also, bioavailability is variable depending on the species, breed, and animal behaviours 
(Toutain et al. 2017). Hence, the ongoing appraisal of the most appropriate veterinary-specific 
breakpoints is essential, particularly for clinical decision-making and the early detection of rare 
and emerging resistance.  
 
13 
The modified error-rate bounding method described by Brunden, Zurenko and Kapik 
(1992) is commonly used by international standards groups such as CLSI to help determine 
‘best-fit’ zone diameter clinical breakpoints. ‘Best-fit' breakpoints are based on predefined 
acceptable levels for misclassification errors (i.e., very major, major, minor errors) described 
by ISO (2006). Several superior model-based approaches have been developed to introduce 
robustness to clinical breakpoint determination (Craig 2000; DePalma, Turnidge & Craig 2017; 
Kronvall, Giske & Kahlmeter 2011).  
Epidemiologic cut-off values (ECOFFs) are used as interpretative criteria in 
surveillance settings. The ECOFF separates bacteria into wild-type and non-wild type 
populations (Kahlmeter et al. 2003). Usually, bacteria assigned to the wild-type population do 
not harbour resistance genes or resistance-mediating mutations, while those of the non-wild 
type population commonly do. Since ECOFFs are not determined by the same criteria used to 
establish clinical breakpoints they are less useful for therapeutic decision-making. Clinical 
breakpoints and ECOFFS may be closely related for some antimicrobial agents and bacterial 
species, however for other combinations, both types of interpretative criteria are far apart. 
Direct comparison of susceptibility data is not always possible as studies use different clinical 
breakpoints (ECDC/EFSA/EMA 2015; Silley 2012), so ECOFFs are recommended for use in 
surveillance to enable direct comparison of bacterial/ antimicrobial resistance datasets 
(Davison, Low & Woolhouse 2000; OIE 2016; Schwarz et al. 2010; Silley, Simjee & Schwarz 
2012). However, fewer ECOFFS are presently available for animal bacteria, making reporting 
and comparison of resistance levels between datasets challenging. For example, at the time of 
writing, there was no zone diameter ECOFF published for E. coli and ceftiofur, a third-
generation cephalosporin used in food animals and categorised as highly important for human 
health by the Australian Strategic and Advisory Group on Antimicrobial Resistance (2018) and 
the OIE (2015a). 
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Many national surveillance programs utilise genotypic and molecular tests to identify 
acquired resistance genes in bacterial isolates from animals, such as the mecA gene associated 
with methicillin-resistance in staphylococci species (Swedres-Svarm 2017), and the gentamicin 
resistance gene aph(2”) in Campylobacter coli isolated from retail chicken meat (USDA 2017). 
When used together, phenotypic and molecular testing offers the best information on the 
management of multi-resistant bacterial infections and detection of new mechanisms of 
bacterial resistance. However, veterinary laboratories have been slow to adopt the technology, 
with Dargatz, Erdman and Harris (2017) reporting 6% of respondents to a survey of America 
veterinary laboratories, used molecular technologies. In Australia, Hardefeldt et al. (2018) 
reported very few veterinary laboratories utilise such technologies. Difficulties in the adoption 
of molecular technologies will need to be overcome before veterinary laboratories can 
incorporate them into testing regimes. This includes understanding the relationship between 
phenotypic testing and resistance genes in different bacterial species, the development of user-
friendly platforms for interpretation of the data, and the cost of infrastructure and labour to 
operate the equipment (Didelot et al. 2012; Frickmann, Masanta & Zautner 2014). 
There is little consensus on standard antimicrobial panels to include for surveillance of 
animal-derived bacterial species. Also, most antimicrobial agents tested in national surveillance 
programs focus on classes of importance to human health. To address the lack of 
standardisation, the European Parliament passed legislation which requires member states to 
test a standard panel of 14 antimicrobial agents for animal-derived Salmonella and E. coli, and 
12 antimicrobial agents for Enterococcus spp (European Union 2013). Some countries, such as 
Denmark, test more antimicrobial agents than specified in the legislation (DANMAP 2017). 
While decisions regarding which antimicrobial agents to test can be difficult, testing large 
numbers of antimicrobial agents is both unnecessary (many antimicrobials have similar in vitro 
activities) and cost-prohibitive (Silley, Simjee & Schwarz 2012). From an epidemiological 
viewpoint, one could argue the ‘over-testing’ of isolates is inefficient when attempting to 
manage a complex antimicrobial resistance surveillance program, particularly for countries 
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with limited resources and infrastructure. A global agreement to test a restricted number of 
antimicrobial agents per bacterial species and animal host will result in cost and time savings, 
enable comparative analysis of datasets, and data generated will be targeted and relevant to 
surveillance objectives. 
 
Diagnostic test evaluation 
An understanding of the performance of laboratory tests is critical to the design and 
interpretation of surveillance and monitoring activities. Uncertainty regarding the performance 
of diagnostic tests raises questions about the quality of data collected and reported by national 
surveillance programs. Accurate data on animal-derived bacteria is essential as it is used to 
inform antimicrobial use policies related to food animals, thus having ramifications for public 
health (Tang et al. 2017). Diagnostic test performance is described by its accuracy and 
precision. Accuracy refers to the deviation of a measurement from its ‘true’ value, while 
precision refers to the closeness of measurements from the same sample (ISO 1994; OIE 
2018a). All diagnostic tests are subject to random and systematic errors, resulting in potential 
misclassification of test values (Gardner, I.A. & Greiner 2000). For phenotypic antimicrobial 
susceptibility tests, misclassification may result in a bacterial isolate being categorised as 
susceptible when it is truly resistant to an antimicrobial agent (worst case scenario in clinical 
settings) or vice versa. Measurement errors can be complex to define, especially for 
antimicrobial susceptibility tests where antimicrobial resistance is rapidly evolving, and the 
criteria used to evaluate resistance status is continually changing. 
 
Accuracy 
Accuracy is traditionally described by diagnostic sensitivity and specificity. Put simply, 
diagnostic sensitivity refers to the ability of a test to correctly identify subjects with the disease 
of interest (e.g., phenotypically resistant), while specificity relates to the ability of a test to 
correctly identify subjects free of disease (e.g., phenotypically susceptible). Estimation of 
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diagnostic sensitivity and specificity is conditional on two factors, (i) knowledge of the true 
status of a bacterium (determined by a reference test), and (ii) the threshold value (e.g., clinical 
breakpoint) used to dichotomise measurement values into test positive (resistant) and test 
negative (susceptible) groups (Dohoo, Martin & Stryhn 2009; Greiner & Gardner 2000). 
Ideally, the reference test is perfect, such that the classification is always correct. However, most 
reference tests are less than perfect and subject to systematic error (Gart & Buck 1966). When 
errors in the reference test are disregarded, bias is present in the accuracy estimates, and these 
estimates are at best ‘relative’. This bias will be such that the accuracy of the comparator test can 
never exceed the errors inherent in the reference test (Enoe, Georgiadis & Johnson 2000; Greiner 
& Gardner 2000). In antimicrobial susceptibility testing, broth microdilution is considered the 
reference test against which all other assays are compared. However, the accuracy of broth 
microdilution is not well understood and probably imperfect since there are few tests considered 
superior other than a limited number of genetic or molecular tests. 
The threshold value used to dichotomise test values has a critical influence on estimates 
of diagnostic sensitivity and specificity (Greiner & Gardner 2000). Depending on the 
distribution of measurement values in a sampled population, the positioning of the threshold 
value will result in varying levels of misclassification errors. Figure 1 shows three different 
zone diameter distributions, with the top graph demonstrating well-separated distributions. Few 
misclassification errors occur when a clinical breakpoint is located somewhere between the two 
populations. In the middle figure, where there is complete overlap, the measurement is of no 
benefit as it is unable to discriminate between isolates that are resistant or susceptible. In the 
bottom graph, a decision about the location of a clinical breakpoint will depend on which type 
of misclassification error is more tolerable. For example, in clinical settings, a breakpoint that 




Figure 1: Hypothetical distributions of resistant (red) and susceptible (blue) bacterial isolates with 
corresponding receiver-operator characteristic (ROC) plots. Adapted from (Schwartz 2012). 
 
The receiver-operating characteristic (ROC) analysis addresses issues associated with 
dichotomising continuous data since it is independent of the threshold-value (Greiner, Pfeiffer 
& Smith 2000). Accuracy is measured by the ROC area-under-the-curve (AUC), which 
describes a test’s ability to separate a group into those with and without the disease (Gardner, 
I. A. & Greiner 2006). In ROC analysis, each point on the curve represents a sensitivity and 
specificity pair corresponding to the decision threshold. A test with perfect discrimination 
(AUC = 1) has a curve which touches the top left corner of the graph, while a test with no 
discriminatory power (AUC = 0.5) has no curve (Swets 1988). Figure 1 demonstrates the ROC 
curve expected with each of the three distributions. The AUC = 1 (100% diagnostic sensitivity 
and specificity) when there is no overlap between populations. However, the AUC estimate 









the two populations completely overlap. Despite the advantages of using ROC analysis to 
determine test accuracy, it does not discriminate between misclassification errors (Greiner & 
Gardner 2000). Further, ROC analysis relies on the use of a ‘perfect’ reference test, which is 
not always available. Although ROC analysis is integral to sensitivity and specificity estimates 
for continuous outcome tests, it is not widely used in veterinary diagnostic test evaluation. This 
is undoubtedly the case for the evaluation of the antimicrobial susceptibility tests where 
measures of accuracy are infrequently reported, particularly for veterinary bacterial pathogens. 
An advantage of reporting robust relative sensitivity and specificity estimates is that 
apparent prevalence (derived from the comparator test) can be corrected to true prevalence 
(derived from the reference test) (Rogan & Gladen 1978). Correcting apparent prevalence to 
true prevalence allows for direct comparison of prevalence estimates from two different tests 
(e.g., disc diffusion and broth microdilution). This feature is highly useful in surveillance where 
estimates of prevalence are important epidemiologic indicators of resistance in the population. 
 
Precision 
Fundamental to the assessment of precision is the statistical estimation of reliability or 
agreement by taking repeated measurements of the same subject (e.g., a bacterial isolate) within 
(repeatability) and between (reproducibility) multiple laboratories. Reliability describes the 
ratio of variability between subjects to the total variability of all measurements, while 
agreement quantifies the degree to which two measurements are identical (Kottner et al. 2011). 
Reliability studies estimate intra- and inter-laboratory reliability from intraclass correlation 
coefficients (ICC) (Barnhart, Haber & Lin 2007; Bartlett & Frost 2008). The reliability ICC 
describes the correlation between repeated measurements on the same sample and across 
multiple samples and takes on values between zero and one, with one (i.e., high reliability) 
representing no measurement error and zero indicating all variability is due to measurement 
error (de Vet et al. 2006). 
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In contrast, agreement studies are designed around the notions of repeatability and 
reproducibility which describe within- and between-observer variability (Barnhart, Haber & 
Lin 2007; ISO 1994). Agreement is a characteristic of the test and does not depend on the 
population in which measurements are made unless bias is present or the true value of the 
measurement varies (Bartlett & Frost 2008). Agreement is measured in the same units as the 
test. Repeatability studies have strict conditions on the measurement of precision (e.g., the same 
technician, same equipment, short times intervals), while reproducibility studies allow for 
changing conditions including different laboratories, and technicians (ISO 1994). 
Reproducibility studies are particularly useful when inferences are made on the wider 
population of potential observers such as veterinary laboratories operating in a national network 
(Barnhart, Haber & Lin 2007; Bartlett & Frost 2008).  
There is no standard approach to the statistical exploration of reliability and agreement, 
as study objectives and design factors such as the sampling strategy and type of data collected 
have a large bearing on assumptions used in estimation model-building (Kottner et al. 2011). 
When reviewing literature on the precision of the disc diffusion assay, previous studies have 
tended to limit evaluation to well-characterised strains such as the ATCC quality control strains 
recommended by CLSI or EUCAST (Hombach et al. 2017; Hombach, Zbinden & Bottger 2013; 
Idelevich et al. 2016; Lehtopolku et al. 2012; Matuschek, Brown & Kahlmeter 2014; Medeiros 
& Crellin 2000; Murray, Zeitinger & Krogstad 1982).  
 
Surveillance of antimicrobial use in animals 
There are many motivations in administering antimicrobial agents to animals. Of most 
concern to the wider community is the use of antimicrobial agents considered medically 
important to people and the non-therapeutic use of antimicrobial agents for growth promotion 
(McEwen, SA & Collignon 2018; O'Neill 2014; WHO 2013). Much of this concern is centred 
on the poorly-defined contribution antimicrobial use in animals makes toward the development 
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of resistance in human bacterial populations (FAO/OIE/WHO 2004; Magouras et al. 2017; 
Tang et al. 2017). While there is a body of evidence demonstrating transfer of antimicrobial 
resistant bacteria between animals and people via direct contact or from food or environmental 
sources (Jordan, D. et al. 2011; Liu et al. 2016; McEwen, SA & Collignon 2018; Van Hoovels 
et al. 2006), there is little consensus regarding the overall effect antimicrobial use in animals 
has on human health. Notwithstanding this uncertainty, there is strong international support for 
the judicious use of antimicrobial agents in animals as a means of protecting public health and 
animal health (FAO/OIE/WHO 2004; United Nations 2016). 
Many countries, particularly those in the European Union, have introduced restrictions 
or prohibitions on the use of important classes of antimicrobials in food animals, legislated 
antimicrobial reduction targets, undertaken benchmarking at the farm-level, and encouraged 
the adoption of antimicrobial stewardship programs (European Medicines Agency and 
European Food Safety Authority 2017). In Australia, a veterinary prescription is required for 
schedule 4 antimicrobial agents, and strict conditions for off-label or unregistered use of 
antimicrobials in food animals has been legislated for decades. The United States has recently 
introduced restrictions on the use of medically important antimicrobial agents in feed and now 
require greater veterinary oversight in the treatment of food animals. Similarly, in Canada, all 
medically important antimicrobial agents now require a veterinary prescription. 
Restrictions on the use of certain antimicrobial classes in food animals have been 
reported to result in a reduction in antimicrobial resistance levels in those species (Aarestrup, 
FM et al. 2001; Bengtsson & Wierup 2006). For example, when the European Commission 
banned the use of avoparcin in animals in 1997, there was a marked reduction in the prevalence 
of vancomycin-resistant enterococci (VRE) in poultry faecal samples. Demark reported a 
decrease in VRE prevalence in poultry samples from over 80% in 1995, to less than 5% in 1998 
(Aarestrup, F 2015), and the Netherlands reported a decrease from 80% to 31% in the two years 
between 1997-1999 (van den Bogaard, Bruinsma & Stobberingh 2000). In Australia, 
fluoroquinolones and fourth-generation cephalosporins have never been registered for use in 
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livestock, and consequently, bacterial resistance to these antimicrobial classes in livestock has 
not been reported (Cheng et al. 2012). When Canadian chicken producers voluntarily withdrew 
from using ceftiofur in 2005, the prevalence of ceftiofur resistance in Salmonella Heidelberg 
isolated from retail chicken meat dropped from over 60% to 7% by 2006. When ceftiofur use 
was partially reinstated in 2007, the prevalence of ceftiofur resistance in Salmonella Heidelberg 
strains increased to 18% by 2008 (Dutil et al. 2010). However, restrictions on antimicrobial use 
on their own may not eliminate resistant genes from an animal population, with recent studies 
demonstrating that for some antimicrobial agents such as avoparcin and ceftiofur, low-level 
prevalence of organisms resistant to these drugs can remain in a population of animals over 
time (Abraham et al. 2018; DANMAP 2017). Consequently, restriction or reduction in the use 
of an antimicrobial agent does not inevitably lead to the complete elimination of resistance 
(EMA/AMEG 2019). 
Most national surveillance programs do not collect antimicrobial usage data from 
companion animals, except for a small number of countries, including Denmark and Sweden 
(DANMAP 2017; Swedres-Svarm 2017). Consequently, it is almost impossible to determine 
the extent of antimicrobial use and the potential effects this use has on the development of 
resistance in companion animals (Guardabassi, Schwarz & Lloyd 2004; Rushton 2015). Given 
there is limited legislative oversight, and a reported higher propensity to use antimicrobials of 
critical importance to humans in companion animal medicine, it is imperative that data is 
collected on the extent of antimicrobial use this sector. For example, Buckland et al. (2016) 
reported in their UK study of 374 small animals veterinary clinics that of all antimicrobial 
events described, 60% of events in dogs and 81% of events in cats were prescribed antimicrobial 
agents classified as critically important to human health. Other studies have also described a 
reliance on critically important antimicrobial agents in companion animals (Barber, Miller & 
McNamara 2003; Guardabassi, Schwarz & Lloyd 2004; Murphy et al. 2012; Smith et al. 2018). 
In Australia, it was reported that 18% of antimicrobial events used fluoroquinolones to treat 
dogs empirically, and 16% of antimicrobial events used a third-generation cephalosporin (i.e., 
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cefovecin) for empirical treatment of cats (Hardefeldt et al. 2017). The study by Hardefeldt et 
al. (2017) also reported rates of use of critically important antimicrobial agents were 
substantially increased in pets with chronic conditions. Given direct contact is considered a 
likely transmission method of resistant bacteria between humans and pets, capturing usage data 
could be of enormous benefit in understanding the epidemiology of localised antimicrobial 
resistance spread, and the development of interventions and stewardship programs that aim to 
minimise the use of critically important antimicrobial agents in pets (Guardabassi 2013; Tang 
et al. 2017) 
Information on antimicrobial use in food animals is not readily available in most 
countries, so the quantity and type of antimicrobial agents used in each sector are mostly 
unknown. For instance, in 2017, just 107 member countries were able to contribute quantitative 
antimicrobial use data to the OIE global database for the monitoring of antimicrobial agents, 
with most information limited to sales and import data (OIE 2017). In Australia, antimicrobial 
use data in animals are limited to nationally aggregated sales data with little other 
accompanying information (Australian Pesticides and Veterinary Medicines Authority 2014). 
Thus, alternative sources for collecting antimicrobial use data in food animals is needed in 
Australia. Few countries, other than Denmark and the Netherlands have implemented nation-
wide automated monitoring systems (DANMAP 2017; Stege et al. 2003). These systems collect 
clinic and farm-level data, which is far more useful for developing effective interventions to 
manage antimicrobial use in animals. Other software-based monitoring systems such as 
VetCompass and SAVSNET, have been shown to be minimally intrusive in the collection of 
prescription-level data from small animal practices, however both require substantial resource 
allocation to extract and analyse data given the absence of standardisation of veterinary record-
keeping (Buckland et al. 2016; Singleton et al. 2018).  
Perhaps the most practical alternative to automated systems is the structured 
questionnaire, where point-prevalence data obtained from veterinarians and producers can be 
used for detailed analysis of antimicrobial use by species, production type, age class, and 
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disease syndromes. While questionnaires have well-recognised limitations, they are a proven 
method for data collection in the scientific literature (Bowling 2005). Questionnaires can be 
efficient, standardised, affordable, confidential, time-flexible, and adaptable for use in multiple 
species and over-time (Jordan, D. et al. 2009; WHO 2013). For food animals, the cooperation 
of farmers and veterinarians is critical to obtaining accurate antimicrobial use data, particularly 
given the complex issues and sensitivities surrounding the quantity, types, and reasons for use. 
Inevitably, multi-stakeholder involvement will be required to encourage farmers and 
veterinarians to share antimicrobial use data in food animals voluntarily. Engagement with 
multiple stakeholders can lead to increased complexity in the planning, execution, and analysis 
of results, and thereby potentially impact on the quality of inferences arising from the survey.  
The interpretation of antimicrobial use data is challenging when there are several 
metrics used to quantify the data, and the information requirements of stakeholders are very 
different. Despite the efforts of national surveillance programs, it is widely recognised that the 
reporting of antimicrobial sales data is of limited benefit (Cameron, A & McAllister 2016; 
Guardabassi, Schwarz & Lloyd 2004; Rushton 2015; Silley, Simjee & Schwarz 2012). Silley, 
Simjee and Schwarz (2012) contend that between-country comparisons on antimicrobial use 
per species based on the tonnage of antimicrobial agents sold are misleading and that these data 
should never be used as proof of causality between animal use and resistance trends in people. 
However, others appear content to draw such conclusions, notwithstanding the limitations in 
the quality and accuracy of the data (Chantziaras et al. 2014; ECDC/EFSA/EMA 2015; Tang 
et al. 2017). Until we can reliably, accurately, and routinely collect antimicrobial use data at the 







The case for enhanced surveillance of antimicrobial resistance in animals 
The term efficiency refers to the ability to accomplish a task with a minimum of 
resources, saving money, time, and labor. As such, it is essential to consider whether 
efficiencies can be identified in the conduct of antimicrobial resistance surveillance without 
compromising program objectives (which may not be sufficiently detailed in the first instance). 
Many of the challenges associated with surveillance of animals are yet to be overcome. Existing 
national surveillance programs have evolved from a strong microbiological approach to 
surveillance where the emphasis is placed on measuring the attributes of the individual isolate 
rather than defining the status of the broader population. In these programs, relatively small 
numbers of bacterial isolates per host species are tested against many antimicrobial agents. 
While this strategy yields excellent information regarding the resistance status of each isolate 
evaluated (high internal validity), it is an expensive approach to conducting surveillance in 
animals, has questionable external validity, may not be fit for all intended purposes when 
applied to surveillance in food animals (i.e. a focus at the population level), or is well suited to 
all countries, especially those with limited budgets. 
An aspect of antimicrobial resistance surveillance missing from most national programs 
is the meaningfulness of the data to the livestock sector. Surveillance objectives and 
interventions are focused on public health outcomes without providing many benefits to 
participating livestock sectors, such as managing endemic bacterial diseases of livestock. 
Moreover, few programs report resistance and antimicrobial use data relevant to companion 
animals, further eroding opportunities to address antimicrobial resistance issues in animals 
adequately. The expansion of surveillance programs to evaluate bacterial pathogens from 
animals would have a positive effect on the implementation of strategies which aim to contain 
antimicrobial resistance in animals and provide veterinarians with the necessary information to 
optimise antimicrobial use. 
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Scope and aims of this thesis 
This thesis presented an opportunity to identify innovative solutions to address issues 
associated with the quality of data arising from national surveillance programs for antimicrobial 
resistance. Questions raised and discussed in this thesis included: 
1. Is the disc diffusion assay accurate for use in a national surveillance program?  
There is an opportunity to collect susceptibility data from veterinary laboratories for use in 
national surveillance provided results from disc diffusion are comparable to broth 
microdilution. In this thesis, I evaluated the accuracy of disc diffusion relative to broth 
microdilution for two important pathogens of animals – E. coli and S. pseudintermedius 
(Chapters 2 and 3). The overlap between these two chapters is only partial since Chapter 3 
expands on the methodology of its predecessor by including the evaluation of phenotypic assays 
against genetic approaches for detecting the presence of resistance determinants. 
 
2. How precise is the disc diffusion assay in veterinary diagnostic laboratories? 
 
Understanding measurement imprecision (variability) in a diagnostic test is critical for 
interpretation of results. Standardisation of protocols is necessary to ensure data can be repeated 
by different technicians either within the same laboratory or reproduced at different 
laboratories. It is essential for laboratories participating in national surveillance to adopt 
standardised protocols when performing the disc diffusion assay. Research into the repeatability 
and reproducibility of disc diffusion testing in Australian veterinary diagnostic laboratories will 





3. Is robotic technology possible for the evaluation of antimicrobial resistance in large 
numbers of commensal bacteria? 
 
Current surveillance approaches suffer from very small sample sizes. The advantage of larger 
sample sizes is that it overcomes serious design weakness related to inadequate coverage of 
animal populations and generates more precise estimates of prevalence. If laboratory capacity 
is increased through the adoption of efficient testing methods, there is scope to increase the 
number of isolates appraised in surveillance. Furthermore, evaluation of the optimal number of 
antimicrobial agents to be included in a panel will reduce costs and may free up resources to 
evaluate more isolates. While it was intended that this thesis undertake a pilot study using high-
throughput robotic technologies, the robotic equipment was not available in time for research 
to take place. This remains an important area of research to explore efficiency gains in 
surveillance. 
 
4. How well do questionnaires perform as part of a stakeholder-driven approach to collect 
farm-level data on antimicrobial use? 
Data based on antimicrobial sales is of limited value in the design of interventions to optimise 
antimicrobial use in livestock. Capturing antimicrobial usage data and information on 
stewardship practices at the farm-level will help identify factors that contribute to the 
persistence of resistant bacteria. However, the cooperation of herd-owners and veterinarians is 
critical to obtaining such data given the complex issues that exist involving specific 
antimicrobial agents, diseases, and treatment regimes. Herd-level data also benefit livestock 
producers and veterinarians in the development of prescribing guidelines and stewardship 
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Relative Performance of Antimicrobial Susceptibility Assays on Clinical 








Phenotypic assays such as disc diffusion and broth microdilution are used in clinical and 
surveillance settings to determine the antimicrobial susceptibility of bacterial isolates. While 
broth microdilution is the preferred assay for surveillance, disc diffusion is commonly used in 
veterinary diagnostic laboratories. There is considerable scope to acquire disc diffusion data 
from veterinary laboratories for the surveillance of bacterial pathogens provided the results are 
comparable to broth microdilution. However, the performance of phenotypic assays is poorly 
understood, as they are used in veterinary diagnostic laboratories. This raises questions about 
the quality of information reported by national surveillance programs for antimicrobial 
resistance. Thus, the aim of this study was to evaluate the accuracy of disc diffusion relative to 
broth microdilution (the reference test) for clinical Escherichia coli isolates (n=994) derived 
from companion animals. In this study, conventional statistical methods are used to evaluate 
the accuracy of disc diffusion relative to broth microdilution, including the reporting of relative 
diagnostic sensitivity and specificity, likelihood ratio pairs, and receiver-operating 





































Diagnostic accuracy of phenotypic assays for determining 
antimicrobial resistance status in Staphylococcus pseudintermedius 








The preceding chapter detailed the accuracy of disc diffusion relative to broth 
microdilution for clinical Escherichia coli isolates derived from animals. In this chapter, the 
accuracy of disc diffusion relative to broth microdilution is evaluated against Staphylococcus. 
pseudintermedius, an important and ubiquitous bacterium of dogs. Chapter 3 builds on Chapter 
2 by evaluating the performance of both disc diffusion and broth microdilution to a more 
accurate test – mecA real-time PCR for the prediction of methicillin resistance. Few studies 
have assessed the performance attributes of broth microdilution even though it is widely 
considered to be the reference test to which all other phenotypic assays are compared. As 
genetic and molecular technologies become accessible, opportunities exist to evaluate the 
performance of broth microdilution fully. In this study, paired zone diameter and minimum 
inhibitory concentration (MIC) measurements from 614 clinical S. pseudintermedius isolates 
were used in analyses, with isolates also tested by real-time PCR. Conventional statistical 
methods were used to evaluate the accuracy of disc diffusion, including the reporting of 








































Intra- and inter-laboratory agreement of the disc diffusion 









In Chapters 2 and 3, the accuracy of disc diffusion relative to broth microdilution was 
found to be satisfactory for determining susceptibility in clinical Escherichia coli and S. 
pseudintermedius for most antimicrobial agents evaluated. The other component to evaluating 
diagnostic performance is to determine an assay’s precision. Understanding measurement 
imprecision (i.e., variability) in a diagnostic test is critical not only for clinical interpretation 
but also for determining whether a diagnostic test is suitable for use in surveillance activities. 
Hence, in Chapter 4, the precision of disc diffusion was investigated to determine the extent of 
variation in measurements that can be expected when the test is performed in veterinary 
diagnostic laboratories. A test-retest study design was used to determine intra-laboratory 
agreement (repeatability) and inter-laboratory agreement (reproducibility). Repeatability and 
reproducibility estimates provide a practical interpretation of the extent of variation in zone 
diameter measurements expected in veterinary laboratories when testing the same isolate. 
Seven veterinary diagnostic laboratories participated in the study and tested replicates from the 
same twenty clinical E. coli isolates from pigs five times over time. The findings from this 
study, coupled with those from Chapters 2 and 3, will help determine whether antimicrobial 
susceptibility data from disc diffusion can be acquired from veterinary laboratories for use in 














































Management of antimicrobial resistance is aided by the collection of data on the use of 
antimicrobial agents via questionnaires or other survey methods. Information collected at the 
farm-level is of most value in quantifying antimicrobial agents used, the purposes of use, and 
the diseases commonly treated. Farm-level data is invaluable in the formulation of relevant, 
industry-specific antimicrobial stewardship programs, prescribing guidelines, and other 
communication tools which help manage antimicrobial resistance in animals. In Chapter 5, the 
beef feedlot sector was used as a case study to examine the usefulness of a common survey 
method (i.e., self-administered mailed questionnaire) to obtain information on antimicrobial use 
at the farm-level. This approach relies heavily on farmer participation and support in collecting 
data which can be legally, commercially, and socially sensitive. Very often, industry bodies 
associated with the livestock sector are involved in design of the survey. Hence, a strong 
collaborative approach between all stakeholders is needed to ensure a sufficiently high response 
rate to make inferences on the broader population. In this study, beef feedlot operators were 
asked about their antimicrobial use during the previous twelve months, the purposes of use, and 
the treatment of common disease syndromes. Responses from the survey were used to develop 

































































This thesis examined the quality of measurement systems used to evaluate antimicrobial 
resistance and antimicrobial use in animal populations. The four studies in this thesis expand 
our understanding of the data generated from phenotypic antimicrobial susceptibility tests 
(Chapters 2, 3, 4) and from questionnaires used to obtain information on antimicrobial use 
(Chapter 5). 
The quality of information derived from surveillance activities is strongly dependent on 
accuracy and reliability – of the sampling methodology and the measurement tools used to 
collect information. However, for animals, the objectives of national programs are often poorly 
defined, the sampling and testing protocols may not be purposefully designed, and surveillance 
outputs can fall short of providing the information required to guide policies. As exponentially 
more research and surveillance activities are undertaken on antimicrobial resistance, there is a 
strong need for critical appraisal of the quality, usefulness, and credibility of the data generated. 
For instance, what are the objectives of the research or surveillance activity? What decisions 
do these objectives support? And, will the data properly inform decision-making? Research and 
other information-gathering activities cannot be considered surveillance if their only goal is to 
collect data for its intrinsic value. The aim of surveillance should be the ongoing collection of 
data to guide policy and actions, and in doing so, needs standardised and accepted methods and 
a strong understanding of the performance of the tests used to generate the data. 
This discussion presents an opportunity to examine the findings of each research area 






Is disc diffusion accurate for use in national surveillance programs?  
Phenotypic assays are the backbone of national programs for surveillance of 
antimicrobial resistance. This is especially so in resource-limited settings such as the veterinary 
sector, where there has been slow adoption of genetic and molecular technologies. At present, 
the performance of phenotypic assays is poorly defined in both human and animal settings. This 
raises questions about the quality of information reported by national surveillance programs. 
Thus, the accuracy and reliability of phenotypic susceptibility data must be evaluated, and this 
thesis does this. 
Chapters 2 and 3 evaluated the diagnostic test accuracy of disc diffusion relative to broth 
microdilution (the accepted reference standard) for a range of antimicrobial classes and two 
important bacterial pathogens of animals, E. coli (Chapter 2) and S. pseudintermedius (Chapter 
3). Where Chapter 2 evaluated the diagnostic accuracy of disc diffusion relative to broth 
microdilution, Chapter 3 built on this approach by assessing both disc diffusion and broth 
microdilution to real-time PCR to determine methicillin resistance. Few studies have evaluated 
broth microdilution to assays that can be assumed to be more accurate. However, as genetic and 
molecular technologies become more widely available, opportunities exist to evaluate broth 
microdilution. Indeed, the evidence presented in Chapter 3 demonstrates this process for S. 
pseudintermedius (a ubiquitous opportunistic pathogen of dogs). 
For most antimicrobials evaluated, disc diffusion was found to be accurate at predicting the 
antimicrobial susceptibility of clinical E. coli and S. pseudintermedius that could otherwise be 
determined by broth microdilution. The ability of disc diffusion to correctly classify isolates, 
relative to broth microdilution, varied with the antimicrobial and clinical breakpoint used to 
dichotomise the data. For example, disc diffusion performed strongly for critically important 
antimicrobial classes such as fluoroquinolones (e.g., ciprofloxacin) and third generation 
cephalosporins (e.g., ceftiofur) and first-line antimicrobials such as tetracycline and ampicillin. 
Therefore, the acquisition of data generated by disc diffusion testing in veterinary laboratories 
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could be beneficial in informing our understanding of antimicrobial resistance in animal health 
and public health. However, overlapping populations of susceptible and resistant isolates 
resulted in inferior estimates for some antimicrobials, made worse by the clinical breakpoint 
used to determine status. For example, disc diffusion performed less favourably for amoxicillin, 
amoxicillin-clavulanic acid, and trimethoprim-sulfamethoxazole, where susceptible and 
resistant populations were shown to overlap.  
The reliance on using a threshold value to dichotomise continuous data presents a strong 
justification for using ROC analysis to evaluate test accuracy, although very few diagnostic test 
evaluation studies have done so. ROC has limitations when the reference test is less than 
perfect, as is the case with broth microdilution. More robust estimates of test performance can 
be obtained by using a more accurate reference test (as occurred in Chapter 3) or preferably, by 
using latent class analysis which is not reliant on a perfect reference test (Enoe, Georgiadis & 
Johnson 2000; Johnson, Jones & Gardner 2019; Pepe & Janes 2007). However, the use of a 
more accurate reference test is based on there being such a test in existence and that it is 
affordable and accessible, while for the studies reported in this thesis, assumptions which 
underlie latent class analysis could not be met. 
Notwithstanding these limitations, the use of an extensive national collection of clinical E. 
coli (n=994) and S. pseudintermedius (n=614) isolates has greatly strengthened the analysis of 
phenotypic assays. Indeed, few national collections from veterinary sources have been reported 
elsewhere and which are comparable or superior in size and geographic representativeness. 
Therefore, the performance estimates reported in the thesis can be considered sufficiently robust 
such that the relative diagnostic sensitivity and specificity of disc diffusion for a range of 
antimicrobials to E. coli and S. pseudintermedius can be co-opted for use in surveillance to 
correct for true prevalence, thereby allowing comparison with prevalence estimates generated 
from broth microdilution data. 
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The ability of phenotypic assays to yield discrepant results was highlighted in Chapters 2 
and 3 and became a focus for further investigation in Chapter 4. These disagreements are 
preserved in the analyses to faithfully reflect the measurement error inherent in all tests and 
conditions that arise in diagnostic laboratories. However, very often in microbiological 
research, the solution to resolving a disagreement is to retest isolates to confirm ‘true’ status 
using a reference test (e.g., broth microdilution) and or a ‘resolver’ test (e.g., PCR). This 
approach, known as discrepant analysis, usually results in an overestimation of the performance 
of a comparator test (Green, Black & Johnson 1998; Miller 2012). That is, where both test 
results agree, the status of an isolate is considered ‘true’; however, where two test results 
disagree, re-testing shifts a measurement from disagreement to agreement. Resolving 
disagreement between measurements by repeat testing should be discontinued. If we are to truly 
understand the validity of these data, a more rigorous approach to the evaluation of diagnostic 
test performance is needed, similar to that undertaken in Chapters 2 and 3, or by latent class 
analysis when the underlying assumptions can be met (Johnson, Jones & Gardner 2019). 
 
How precise is disc diffusion when used in veterinary diagnostic laboratories? 
Anecdotally, it appears few technicians performing and interpreting phenotypic assays 
understand what level of variability they can expect if the same isolate is assessed on multiple 
occasions. Chapter 4, therefore examined the intra-laboratory agreement (repeatability) and 
inter-laboratory agreement (reproducibility) of disc diffusion in veterinary diagnostic 
laboratories to measure this variability and to understand whether the assay has a role in the 
surveillance of antimicrobial resistance. Repeatability and reproducibility estimates provide a 
practical interpretation of the extent of variation in zone diameter measurements expected in 
diagnostic laboratories when testing the same isolate.  
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The precision of disc diffusion was found to be satisfactory, although the extent of variation 
recorded for some antimicrobials, including ampicillin and trimethoprim-sulfamethoxazole, 
was of concern. Measurement variation is critical the closer the zone diameter measurement is 
to the clinical breakpoint, where the likelihood of misclassification is high. This was seen in 
Chapter 4 for isolates with marginal susceptibility (e.g., ampicillin) and for antimicrobials 
where zone edges were difficult to read (e.g., trimethoprim-sulfamethoxazole). Therefore, when 
defining which antimicrobials to include in testing panels for surveillance, a critical 
consideration should be the ability of those antimicrobials to yield reliable zone diameters, 
especially when there are inherent difficulties in reading zone edges. While this thesis did not 
examine sources contributing to the variation seen in zone diameters, it is postulated that errors 
in manual measurement make a substantial contribution to this variation (Hombach, Zbinden 
& Bottger 2013; Idelevich et al. 2016). Consequently, the adoption of automated zone readers 
to reduce variation associated with visual reading is a recommendation of this thesis. 
 
Interpretation of diagnostic test performance for use in surveillance 
While the findings reported in Chapters 2, 3, and 4 are a product of interactions that occurred 
under the research conditions described in this thesis, they can be generalised to the broader 
population of veterinary laboratories, provided consideration is given to performance estimates 
of the assay. For instance, disc diffusion performs better for some antimicrobials than others. 
This knowledge can be used to design antimicrobial panels for the surveillance of bacterial 
pathogens in animals that reflect antimicrobials that can be (i) reliably measured, and (ii) are of 
interest to animal health. Arising out of the research findings from this thesis is a list of 
recommended antimicrobials for inclusion in disc diffusion testing of E. coli and S. 
pseudintermedius clinical isolates from animals (Table 1). 
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Antimicrobials that performed strongly across CLSI susceptible and resistant clinical 
breakpoints are recommended for inclusion, including ampicillin, ceftiofur, ciprofloxacin, and 
tetracycline. Note, ciprofloxacin was used in this thesis as a representative of the 
fluoroquinolone class as it is commonly used in national surveillance owning to its relevance 
to public health. However, there is a need to evaluate the performance of other fluoroquinolone 
class members specific to animal health, including enrofloxacin and marbofloxacin which are 
important for therapeutic decision-making. Antimicrobials with variable performance require 
further consideration of performance estimates before inclusion. For example, for cefovecin 
and gentamicin, disc diffusion performance was much stronger when the resistant breakpoint 
was applied compared to the susceptible breakpoint. Antimicrobials that performed poorly 
across both breakpoints, namely amoxicillin-clavulanic acid and cefoxitin, are not 
recommended for inclusion in antimicrobial panels. The recommendation to exclude 
amoxicillin-clavulanic acid from disc diffusion testing on E. coli and S. pseudintermedius 
clinical isolates may have ramifications for antimicrobial susceptibility testing in veterinary 
laboratories, given the frequent use of this drug in small animal medicine. 
 
Table 1. Recommended composition of disc diffusion antimicrobial panels for Escherichia coli 
and Staphylococcus pseudintermedius clinical isolates from animals. 
Inclusion in 
antimicrobial panel 
Escherichia coli Staphylococcus pseudintermedius 
Yes ampicillin, ceftiofur, ciprofloxacin, 
tetracycline 
chloramphenicol, ciprofloxacin†, 
clindamycin, oxacillin, tetracycline 




cefovecin, cephalothin, gentamicin, 
trimethoprim-sulfamethoxazole 
cefovecin, rifampicin 
Unable to determine* amikacin, imipenem  
† Ciprofloxacin is representative of the fluoroquinolone class, however, there is a need to evaluate the performance of other 
fluoroquinolone class members specific to animal health, including enrofloxacin and marbofloxacin.  
*All isolates were susceptible to the antimicrobial. 
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Knowledge of the extent of laboratory-to-laboratory variation in the measurement of zone 
diameters is not only valuable for participation in surveillance programs, but this information 
can also be used to standardise the disc diffusion assay further to minimise measurement error. 
Indeed, the findings reported in this thesis support the hypothesis that susceptibility results from 
disc diffusion data, as it is generated in veterinary laboratories, can contribute to national 
surveillance programs for animals. However, before this major finding can be acted upon, the 
logistics of acquiring data from diagnostic laboratories need to be further considered. 
Specifically, assessment of the quality of susceptibility data and the laboratory information 
management systems (LIMS) used in diagnostic laboratories must be undertaken since the data 
required for a surveillance system is different from what is necessary for clinical diagnosis. 
Further, issues associated with the highly selective nature of clinical submissions, potentially 
missing data on important epidemiological covariates (e.g., demographic data), and 
standardisation of test protocols also need to be studied. Diagnostic stewardship, championed 
by WHO (2017a), with its key objective of providing accurate and representative data on 
antimicrobial resistance, and the establishment of ‘surveillance sites’ responsible for collecting 
data at the local level, are important concepts which should be actively pursued in animal health. 
 
How well do questionnaires perform to collect farm-level antimicrobial usage data? 
The management of antimicrobial resistance is aided by the surveillance of two 
characteristics of the population of bacteria and animals. Firstly, the collection of diagnostic 
data on resistance in bacterial pathogens or commensal organisms, and secondly, the collection 
of data on the use of antimicrobial agents via questionnaires or other survey tools. There are 
many potential sampling points for the collection of information on antimicrobial use but of 
interest to this thesis is data collected at the farm-level. Farm-level data provides information 
on actual antimicrobial use as opposed to veterinary-clinic level data, which only provides 
information on the prescription of antimicrobial agents. As such, farm-level data is invaluable 
in the formulation of relevant, industry-specific antimicrobial stewardship programs.  
102 
In Chapter 5, the beef feedlot sector was used as a case study to examine the usefulness of 
a common survey method (i.e., self-administered mailed questionnaire) to obtain information 
on antimicrobial use at the farm-level. This survey process, when used to collect data on 
livestock sectors, is expected to be driven by industry and, consequently, faces several 
methodological constraints including different stakeholder needs, budget restrictions, and 
variable farmer engagement.  
The questionnaire administered in Chapter 5 included a complex array of questions on the 
antimicrobial classes used on-farm in the previous twelve months, purposes of use, disease 
syndromes, and proportions of animals treated. Overall, the use of antimicrobial agents reported 
by respondents was determined to be appropriate for the purpose indicated, and there was a 
strong preference for antimicrobial classes of low importance, or not used, in human medicine 
including tetracyclines, penicillins, macrolides, and ionophores. However, a major limitation 
of this study was the low response rate (16%). While a low response rate does not necessarily 
equate to data that cannot add useful understanding, the risk of non-response bias is higher 
(Murdoch et al. 2014). The complexity of a questionnaire substantially influences the response 
rate and may also impact on the quality of information collected. For example, a questionnaire 
that is lengthy, complex, and asks many commercially, legally, and socially sensitive questions 
are unlikely to garner a high response rate. This represents a lost opportunity to collect data 
needed to inform decision-making. Indeed, the questionnaire used in Chapter 5 is a case study 
in the development of a survey instrument that was not well optimised for its purpose. The final 
design of this questionnaire was the product of multiple stakeholder involvement, coupled with 
poorly defined objectives for conducting the survey. As a result, control over the design of the 
survey was lost in the desire to obtain as much information as possible. Further, the complexity 
of the questionnaire likely placed a considerable cognitive burden on potential respondents, 
which contributed to the low response rate. 
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When designing questionnaires intended for farmers, the mistakes made in this survey 
should be avoided. More reliable methods of survey delivery should be considered for the on-
going collection of antimicrobial use data at the farm-level. Other survey methods may increase 
the response rate and usefulness of the data for analysis. Before undertaking surveys at the farm-
level, further consideration should be given to the type and quantity of data required for analysis 
and the reporting of antimicrobial use to the OIE (OIE 2017). Future surveys should also look 
to quantify antimicrobial use to allow for the calculation of metrics which not only meet OIE 
reporting requirements but can also be used to inform prescribing guidelines. 
A key benefit of questionnaires is its value in informing behaviours and driving social 
change. And so, while the response rate experienced in this study meant we were unable to 
make inferences to the wider population, the data has been valuable in supporting the beef 
feedlot industry’s development of antimicrobial stewardship guidelines and a training program 
(Meat & Livestock Australia 2018) and has also acted as a starting point for other livestock 
sectors to evaluate their antimicrobial use. This is an example of participatory research whereby 
industry leaders, farmers, researchers, and government can come together to enhance data 




The utility of the Antimicrobial agent Use Risk Matrix 
Communicating complex issues such as antimicrobial stewardship is challenging given the 
range of factors influencing antimicrobial use in food animals. Simple communication tools 
that engage farmers and veterinarians are essential in driving change in behaviours. One such 
communication tool I developed as a result of Chapter 5 of this thesis is the Antimicrobial agent 
Use Risk Matrix for beef feedlots (Figure 1). The risk assessment matrix categorises the risk of 
antimicrobial use practices at individual feedlots based on an overall assessment of behaviours 
and antimicrobial-associated factors. Behaviours include whether a veterinary treatment 
protocol has been issued, correct dosing and treatment periods are observed, and records are 
maintained. Antimicrobial-associated factors include the proportion of animals treated in the 
past 12 months, the importance ranking of antimicrobial use, and route of administration. Scores 
are assigned to each element, and the overall score is plotted onto the matrix, identifying the 
category of risk associated with the feedlot. Weightings are assigned to an antimicrobial agent’s 
importance rating according to ASATG and the route of administration. A detailed explanation 
of the weightings applied in the index can be found in Appendix 5. 
There are many advantages to using a risk matrix: it can be made available in different 
formats, it presents complex data in a visual form, it is easily adaptable if risk factors change 
(e.g., importance rankings), and it can be used as a benchmarking tool. The Antimicrobial agent 
Use Risk Matrix could also be a very useful tool for designing risk-based surveillance activities 
in food animals, where strata of animals are sampled according to their exposure to 
antimicrobial agents and the behaviours of those who care for them. However, there are 
limitations to using risk matrices – the assignment of risk can be subjective and may assign high 
risk to factors which are a small risk or vice versa, and the index may oversimplify the 
complexity of antimicrobial use on farms. Notwithstanding these limitations, the purpose of the 
Antimicrobial agent Use Risk Matrix is to be an interactive tool which engages farmers and 
veterinarians on the complex issues associated with antimicrobial resistance and use. 
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Figure 1. Antimicrobial agent Use Risk Index for beef feedlots based on the risk associated with the behaviour towards antimicrobial agent use and actual 




If passively acquired laboratory data is to contribute to national surveillance of antimicrobial 
resistance in bacterial pathogens from animals, further study is suggested in the following areas: 
 
1. Diagnostic test performance 
Further understanding of the performance of disc diffusion and broth microdilution for bacterial 
pathogens of interest to national surveillance is needed. In this thesis, the performance of disc 
diffusion for the two organisms evaluated was reliant on characteristics of the antimicrobial 
agent, the interpretative criteria used to determine susceptibility, and the accuracy of broth 
microdilution (as the reference assay). Since these factors change with the bacterial species 
under evaluation, it is not appropriate to generalise the performance of disc diffusion to other 
bacteria of interest to national surveillance. Also, the performance of broth microdilution must 
be evaluated to ensure the quality of MIC data generated for surveillance. 
 
2. Quality of phenotypic data in veterinary diagnostic laboratories 
A thorough evaluation of the quality of disc diffusion and MIC susceptibility data as it is 
generated in veterinary laboratories is needed before passive surveillance can be instituted. This 
includes the evaluation of recording and reporting of quantitative results, the ease of data 
retrieval from existing laboratory information systems (LIMS), and the adequacy of laboratory 
submission forms for epidemiological evaluation. Also, the coverage of isolates derived from 






3. Establishment of veterinary diagnostic laboratory trial ‘surveillance sites’ in Australia 
Consideration should be given to the establishment of a trial of veterinary diagnostic 
laboratory ‘surveillance sites’ similar to those used in human antimicrobial resistance 
surveillance. The trial would ascertain if it is practical for veterinary diagnostic laboratories to 
adopt standardised protocols for phenotypic assays (broth microdilution and disc diffusion), use 
stipulated antimicrobial agent panels and consistently record and report susceptibility data for 
targeted bacterial pathogens, alongside the day-to-day evaluation of clinical submissions. For 
this to be a success, clinical microbiologists, epidemiologists, and regulators must be able to 
reach consensus on the most advantageous approach to passive surveillance within diagnostic 
laboratories. 
 
4. Collection of farm-level antimicrobial use data 
Improved survey methods are needed to collect high-quality farm-level data on 
antimicrobial use. Collection methods must be on-going to monitor trends over time and 
evaluate the impact of interventions to manage antimicrobial resistance. The antimicrobial use 
data collected must meet OIE reporting requirements to enable international comparisons. 
Industry leaders and government must collaborate to identify ways to maximise veterinary and 
farmer engagement in the collection of antimicrobial data. 
 
5. Effective communication of antimicrobial resistance in animals 
Further study is needed to develop simple, interactive communication tools, such as the 
Antimicrobial agent Use Risk Matrix, which can drive behavioural change among veterinarians 
and farmers. Understanding factors that influence antimicrobial use by veterinarians and 






The research presented in this thesis has identified that for bacterial pathogens, susceptibility 
data from disc diffusion or broth microdilution generated in veterinary laboratories can 
contribute to national surveillance. This information, coupled with data from surveys of 
antimicrobial use at the farm-level, will be of substantial benefit to the development of 
interventions aimed at containing antimicrobial resistance in animals. Collaboration between 
veterinary laboratories, farmers, veterinarians, and regulators is essential to ensure the 
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Supplementary table 1 Diagnostic performance estimates of disc diffusion relative to broth microdilution for 994 clinical Escherichia coli isolates 
from animals using CLSI susceptible and resistant breakpoints. DSe, diagnostic sensitivity; DSp, diagnostic specificity; AUC, area under the curve. 















0.23(0.20, 0.26) 0.97 (0.96, 1.0) 0.82 (0.79, 0.85) 0.79 (0.70, 0.87) 0.99 (0.99, 1.0) 0.98 (0.96, 1.0) 
Amikacin NA 0.99 (0.98, 1.0) NA NA 1.0 (0.99, 1.0) NA 
Ampicillin 0.93 (0.90, 0.96) 0.81 (0.77, 0.84) 0.96 (0.94, 0.97) 0.97 (0.94, 0.99) 0.95 (0.94, 0.97) 0.98 (0.96, 0.99) 
Cephalothin 0.70 (0.67, 0.73) 0.81 (0.71, 0.89) 0.82 (0.77, 0.88) 0.75 (0.69, 0.81) 0.98 (0.97, 0.99) 0.92 (0.89, 0.95) 
Ceftiofur 0.84 (0.76, 0.90) 0.99 (0.98, 0.99) 0.94 (0.91, 0.97) 0.94 (0.87, 0.98) 0.99 (0.98, 1.0) 0.98 (0.96, 1.0) 
Ciprofloxacin 0.96 (0.89, 0.99) 1.0 (0.99, 1.0) 0.99 (0.97, 1.0) 0.99 (0.93, 1.0) 1.0 (0.99, 1.0) 1.0 (1.0, 1.0) 
Cefovecin 0.67 (0.59, 0.75) 0.96 (0.96, 0.97) 0.87 (0.83, 0.91) 0.88 (0.81, 0.94) 0.99 (0.99, 1.0) 0.97 (0.94, 1.0) 
Cefoxitin 0.33 (0.28, 0.40) 1.0(0.99, 1.0) 0.78 (0.74, 0.82) 0.83 (0.73, 0.90) 0.99 (0.99, 1.0) 0.97 (0.95, 1.0) 
Gentamicin 0.50 (0.39, 0.60) 0.99 (0.98, 1.0) 0.82 (0.77, 0.87) 0.92 (0.80, 0.98) 1.0 (0.99, 1.0) 0.97 (0.94, 1.0) 
Imipenem NA 0.99 (0.98, 1.0) NA NA 1.0 (0.99, 1.0) NA 
Trimethoprim-
sulfamethoxazole 
0.70 (0.63, 0.76) 0.99 (0.98, 1.0) 0.93 (0.91, 0.96) 0.72 (0.65, 0.79) 0.99 (0.98, 1.0) 0.94 (0.92, 0.97) 
Tetracycline 0.93 (0.89, 0.96) 0.98 (0.97, 0.99) 0.97 (0.95, 0.99) 0.95 (0.91, 0.98) 0.99 (0.99, 1.0) 0.98 (0.96, 0.99) 
CI, 95% confidence interval (exact).  
NA, not available due to insufficient data for the analysis. 
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Supplementary Table 2 Estimates of likelihood ratio of disc diffusion relative to broth microdilution for 994 clinical Escherichia coli isolates 
using CLSI susceptible and resistant breakpoints. LR+, likelihood ratio of a positive test result; LR-, likelihood ratio of a negative test result. 









Amoxicillin-clavulanic acid 15.8 (5.1, 49.0) 0.79 (0.75, 0.82) 118.1 (52.9, 263.7) 0.21 (0.14, 0.30) 
Amikacin 5.5 (0.72, 42.3) 0.96 (0.88, 1.1) NA NA 
Ampicillin 4.8 (4.1, 5.6) 0.09 (0.06, 0.13) 21.0 (15.0, 29.3) 0.03 (0.02, 0.06) 
Cephalothin 3.7 (2.4, 5.9) 0.37 (0.32, 0.43) 35.4 (22.0, 57.1) 0.25 (0.20, 0.32) 
Ceftiofur 67.3 (37.2, 121.7) 0.16 (0.11, 0.25) 168.4 (70.2, 404.2) 0.06 (0.03, 0.14) 
Ciprofloxacin 220.6 (82.9, 587.1) 0.04 (0.01, 0.12) 454.6 (113.8, 1815.4) 0.01 (0, 0.10) 
Cefovecin 17.2 (12.1, 24.5) 0.34 (0.27, 0.43) 131.2 (58.9, 292.1) 0.12 (0.07, 0.20) 
Cefoxitin 61.8 (22.9, 166.9) 0.67 (0.61, 0.73) 124.9 (56.0, 279.0) 0.18 (0.11, 0.28) 
Gentamicin 63.3 (29.5, 135.9) 0.51 (0.42, 0.62) 289.3 (93.2, 898.1) 0.08 (0.03, 0.21) 
Imipenem 5.0 (1.5, 16.9) 0.94 (0.87, 1.0) NA NA 
Trimethoprim-sulfamethoxazole 68.8 (34.3, 137.9) 0.31 (0.25, 0.38) 72.9 (36.4, 146.1) 0.28 (0.22, 0.35) 
Tetracycline 53.5 (31.8, 90.1) 0.07 (0.04, 0.12) 154.4 (64.4, 370.1) 0.05 (0.03, 0.09) 
CI, 95% confidence interval (exact).  
NA, not available due to insufficient data for the analysis. 
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Supplementary Table 3 Agreement estimates between broth microdilution and disc diffusion for 994 clinical Escherichia coli isolates from 

















Amoxicillin-clavulanic acid 0.79 0.18 <0.001* 0.39 (0.36, 0.42) 0.37 (0.34, 0.40) 0.41 (0.36, 0.44) NA 
Amikacin 0.02 0.01 0.02* 0.97 (0.96, 0.98) 0 (0, 0.21) 0.99 (0.98, 0.99) 0.94 (0.92, 0.96) 
Ampicillin 0.35 0.45 <0.001* 0.85 (0.83, 0.87) 0.81 (0.78, 0.84) 0.87 (0.85, 0.89) 0.70 (0.65, 0.74) 
Cephalothin 0.92 0.66 <0.001* 0.71 (0.67, 0.73) 0.81 (0.79, 0.83) 0.31 (0.26, 0.34) 0.41 (0.35, 0.47) 
Ceftiofur 0.11 0.11 0.20 0.97 (0.96, 0.98) 0.87 (0.81, 0.91) 0.98 (0.98,0.99) 0.94 (0.92, 0.96) 
Ciprofloxacin 0.08 0.08 0.73 0.99 (0.97, 1.0) 0.95 (0.91, 0.98) 1.0 (0.99, 1.0) 0.99 (0.98, 1.0) 
Cefovecin 0.15 0.14 0.08 0.92 (0.90, 0.93) 0.71 (0.66, 0.76) 0.95 (0.94, 0.96) 0.84 (0.80, 0.87) 
Cefoxitin 0.25 0.09 <0.001* 0.83 (0.80, 085) 0.49 (0.44, 0.55) 0.90 (0.88, 0.91) 0.65 (0.61, 0.70) 
Gentamicin 0.10 0.06 <0.001* 0.94 (0.93, 0.96) 0.63 (0.55, 0.71) 0.97 (0.96, 0.98) 0.89 (0.86, 0.92) 
Imipenem 0.04 0.02 <0.001* 0.95 (0.93, 0.96) 0.1 (0, 0.21) 0.97 (0.96, 0.98) 0.89 (0.82, 0.89) 
Trimethoprim-sulfamethoxazole 0.21 0.15 <0.001* 0.93 (0.91, 0.95) 0.80 (0.76, 0.84) 0.96 (0.95, 0.97) 0.86 (0.82, 0.89) 
Tetracycline 0.19 0.19 0.85 0.97 (0.96, 0.98) 0.93 (0.90, 0.95) 0.98 (0.98, 0.99) 0.95 (0.93, 0.97) 
CI, Confidence interval (95% exact). 
NA, not available due to insufficient data for the analysis. 
* Represents a statistically significant mid-p McNemar’s chi-square test (p < 0.05). 
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Supplementary Table 4 Agreement estimates between broth microdilution and disc diffusion for 994 clinical Escherichia coli isolates from 

















Amoxicillin-clavulanic acid 0.10 0.09 <0.001* 0.97 (0.96, 0.98) 0.86 (0.80, 0.90) 0.98 (0.98, 0.99) 0.95 (0.93, 0.97) 
Amikacin 0.02 0.02 0.63 1.0 (0.99, 1.0) 0 (0, 0.60) 1.0 (0.99, 1.0) NA 
Ampicillin 0.28 0.30 <0.001* 0.96 (0.94, 0.97) 0.93 (0.90, 0.95) 0.97 (0.96, 0.98) 0.92 (0.89, 0.94) 
Cephalothin 0.20 0.17 <0.001* 0.94 (0.92, 0.95) 0.82 (0.78, 0.86) 0.96 (0.95, 0.97) 0.87 (0.84, 0.90) 
Ceftiofur 0.10 0.10 0.77 0.99 (0.98, 0.99) 0.94 (0.90, 0.97) 0.99 (0.99, 1.0) 0.98 (0.97, 0.99) 
Ciprofloxacin 0.07 0.07 0.63 1.0 (0.99, 1.0) 0.98 (0.94, 1.0) 1.0 (0.99, 1.0) 0.99 (0.99, 1.0) 
Cefovecin 0.10 0.10 0.17 0.98 (0.97, 0.99) 0.91 (0.86, 0.95) 0.99 (0.98, 1.0) 0.97 (0.94, 0.98) 
Cefoxitin 0.09 0.08 0.05* 0.98 (0.97, 0.99) 0.87 (0.81, 0.92) 0.99 (0.98, 1.0) 0.96 (0.94, 0.98) 
Gentamicin 0.05 0.05 0.73 0.99 (0.99, 1.0) 0.93 (0.86, 0.97) 1.0 (0.99, 1.0) 0.99 (0.98, 1.0) 
Imipenem 0 0 0.2 1.0 (0.99, 1.0) 0 (0, 0.52) 1.0 (0.99, 1.0) 0.99 (0.98, 1.0) 
Trimethoprim-sulfamethoxazole 0.19 0.15 <0.001* 0.94 (0.92, 0.95) 0.82 (0.77, 0.86) 0.96 (0.95, 0.97) 0.88 (0.85, 0.91) 
Tetracycline 0.18 0.18 0.30 0.99 (0.99, 1.0) 0.96 (0.94, 0.98) 0.99 (0.98, 1.0) 0.97 (0.96, 0.99) 
CI, Confidence interval (95% exact). 
NA, not available due to insufficient data for the analysis. 
* Represents a statistically significant mid-p McNemar’s chi-square test (p < 0.05). 
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Supplementary Table 5 Estimates of accuracy of disc diffusion relative to broth microdilution for 994 clinical Escherichia coli isolates from 
animals using zone diameter interpretative criteria produced from the dBETS program. DSE, diagnostic sensitivity; DSp, diagnostic specificity; 
ZD, zone diameter. 























21 0.61 (0.57, 0.64) 0.87 (0.81, 0.91) 0.66 (0.63, 0.69) 15 0.92 (0.85, 0.97) 0.98 (0.97, 0.99) 0.98 (0.97, 0.99) 
Amikacin 16 NA 1.0 (0.99, 1.0) 0.97 (0.96, 0.98) 12 NA 1.0 (0.99, 1.0) 1.0 (0.99, 1.0) 
Ampicillin 11 0.80 (0.76, 0.85) 0.98 (0.96, 0.99) 0.92 (0.90, 0.93) 7 0.96 (0.94, 0.98) 0.98 (0.97, 0.99) 0.97 (0.96, 0.98) 
Cephalothin 18 0.70 (0.67, 0.73) 0.81 (0.71, 0.89) 0.71 (0.68, 0.73) 13 0.68 (0.61, 0.74) 0.99 (0.98, 1.0) 0.93 (0.91, 0.94) 
Ceftiofur 22 0.86 (0.78, 0.92) 0.98 (0.97, 0.99) 0.97 (0.95, 0.98) 18 0.96 (0.90, 0.99) 0.99 (0.97, 1.0) 0.99 (0.98, 1.0) 
Ciprofloxacin 18 0.96 (0.89, 0.99) 1.0 (0.99, 1.0) 1.0 (0.99, 1.0) 11 0.90 (0.80, 0.96) 1.0 (0.99, 1.0) 0.99 (0.98, 1.0) 
Cefovecin 23 0.67 (0.60, 0.75) 0.96 (0.95, 0.97) 0.92 (0.90, 0.93) 19 0.88 (0.81, 0.94) 0.99 (0.99, 1.0) 0.98 (0.97, 0.99) 
Cefoxitin 22 0.43 (0.37, 0.50) 0.97 (0.96, 0.98) 0.83 (0.81, 0.86) 18 0.91 (0.83, 0.96) 0.99 (0.98, 1.0) 0.98 (0.97, 0.99) 
Gentamicin 16 0.50 (0.39, 0.60) 0.99 (0.98, 1.0) 0.94 (0.93, 0.96) 12 0.92 (0.80, 0.98) 1.0 (0.99, 1.0) 0.99 (0.98, 1.0) 
Imipenem 23 NA 0.99 (0.98, 0.99) 0.95 (0.93, 0.96) 15 NA 1.0 (0.99, 1.0) 1.0 (0.99, 1.0) 
Trimethoprim-
sulfamethoxazole 
25 0.87 (0.82, 0.92) 0.86 (0.83, 0.88) 0.86 (0.84, 0.88) 21 0.79 (0.72, 0.84) 0.98 (0.96, 0.99) 0.94 (0.92, 0.96) 
Tetracycline 18 0.93 (0.88, 0.96) 0.99 (0.98, 0.99) 0.97 (0.96, 0.98) 13 0.95 (0.91, 0.98) 0.99 (0.99, 1.0) 0.98 (0.97, 0.99) 





Supplementary Figure 1. Amoxicillin-clavulanic acid - performance of disc diffusion relative 
to broth microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter 
results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) 
two-graph ROC curve. See text for interpretation of plots. 
 
Supplementary Figure 2. Amikacin - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-




Supplementary Figure 3. Ampicillin - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-
graph ROC curve. See text for interpretation of plots. 
 
 
Supplementary Figure 4. Cephalothin - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-




Supplementary Figure 5. Ceftiofur - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-
graph ROC curve. See text for interpretation of plots. 
 
 
Supplementary Figure 6. Ciprofloxacin - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-




Supplementary Figure 7. Cefovecin - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-
graph ROC curve. See text for interpretation of plots. 
 
 
Supplementary Figure 8. Cefoxitin - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-




Supplementary Figure 9. Gentamicin - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-
graph ROC curve. See text for interpretation of plots. 
 
 
Supplementary Figure 10. Imipenem - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-




Supplementary Figure 11. Trimethoprim-sulfamethoxazole - performance of disc diffusion 
relative to broth microdilution for clinical E. coli isolates from animals (i) distribution of zone 
diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), 
and (iii) two-graph ROC curve. See text for interpretation of plots. 
 
 
Supplementary Figure 12. Tetracycline - performance of disc diffusion relative to broth 
microdilution for clinical E. coli isolates from animals (i) distribution of zone diameter results 
(ii) scatterplot of zone diameter (mm) and MIC (µg/ml, depicted on log2 scale), and (iii) two-
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Supplementary Table 1. Agreement estimates between broth microdilution and disc diffusion for 614 canine Staphylococcus pseudintermedius 
isolates from clinical cases. Clinical Laboratory Standards Institute (CLSI) susceptible breakpoints were used to dichotomise MIC and zone 
diameter values. Exact 95% confidence intervals are given. BMD, broth microdilution; DD, disc diffusion; PABAK, prevalence-adjusted bias-
adjusted kappa. 
Antimicrobial % BMD 
resistant 









Amoxicillin-clavulanic acid 10.7 (8.4, 13.5) 5.7 (4.0, 7.8) <0.001* 94.6 (92.5, 96.3) 67.3 (57.3, 76.3) 97.1 (95.9, 98.0) 0.89 (0.86, 0.93) 
Cefovecin 13.5 (10.9, 16.5) 10.6 (8.3, 13.3) <0.001* 95.4 (93.5, 97.6) 81.1 (73.8, 87.1) 97.4 (96.3, 98.3) 0.91 (0.90, 0.96) 
Cefoxitin 2.3 (1.3, 3.8) 1.5 (0.7, 2.8) 0.18 97.9 (96.4, 98.9) 43.5 (23.2, 65.5) 98.2 (98.2, 99.4) 0.96 (0.94, 0.98) 
Cephalothin 7.3 (5.4, 9.7) 5.2 (3.6, 7.3) <0.001* 97.2 (95.6, 98.4) 77.9 (67.0, 86.6) 98.5 (97.6, 99.1) 0.95 (0.92, 0.97) 
Chloramphenicol 6.5 (4.7, 8.8) 5.5 (3.9, 7.7) 0.02* 99.0 (97.8, 99.6) 91.9 (83.2,97.0) 99.5 (98.9, 99.8) 0.98 (0.97, 1.0) 
Ciprofloxacin 9.0 (6.8, 11.5) 8.3 (6.3, 10.8) 0.13 99.0 (97.9, 99.6) 94.3 (88.1, 97.9) 99.5 (98.8, 99.8) 0.98 (0.97, 1.0) 
Clindamycin 13.4 (10.8, 16.3) 13.8 (11.2, 16.8) 0.22 99.2 (98.1, 99.7) 97.0 (93.2, 99.0) 99.5 (98.9, 99.9) 0.98 (0.97, 1.0) 
Oxacillin 12.9 (10.3, 14.8) 11.4 (9.0, 14.2) <0.001* 98.5 (97.2, 99.3) 94.0 (88.8, 97.2) 99.2 (98.4, 99.6) 0.97 (0.95, 0.99) 
Rifampicin 0.8 (0.3, 18.9) 1.1 (4.6, 2.3) 0.37 99.4 (98.3, 99.8) 66.7 (34.9, 90.1) 99.7 (99.2, 99.9) 0.99 (0.97, 1.0) 
Tetracycline 22.3 (19.1, 25.8) 22.8 (19.9, 26.3) 0.31 96.3 (94.4, 97.6) 91.8 (87.9, 94.7) 97.6 (96.4, 98.5) 0.93 (0.90, 0.96) 
* Significant mid-p McNemar’s chi-square test (p<0.05). 
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Supplementary Table 2. Agreement estimates between broth microdilution and disc diffusion for 614 canine Staphylococcus pseudintermedius 
isolates from clinical cases. Clinical Laboratory Standards Institute (CLSI) resistant breakpoints were used to dichotomise MIC and zone diameter 
values. Exact 95% confidence intervals for estimates are given. BMD, broth microdilution; DD, disc diffusion; PABAK, prevalence-adjusted bias-
adjusted kappa. 









Amoxicillin-clavulanic acid 10.7 (8.4, 13.5) 5.7 (4.0, 7.8) <0.001* 94.6 (92.5, 96.3) 67.3 (57.3, 76.3) 97.1 (95.9, 98.0) 0.89 (0.86, 0.93) 
Cefovecin 10.3 (8.0, 12.9) 10.1 (7.8, 12.8) 0.81 97.2 (95.6, 98.4) 86.4 (79.1, 91.9) 98.5 (97.5, 99.1) 0.95 (0.92, 0.97) 
Cefoxitin 2.3 (1.3, 3.8) 1.5 (6.7, 2.8) 0.18 97.9 (96.4, 98.9) 43.5 (23.2, 65.5) 98.9 (98.2, 99.4) 0.96 (0.94, 0.98) 
Cephalothin 6.4 (4.6, 8.6) 2.9 (1.8, 4.6) <0.001* 96.3 (94.4, 97.6) 59.7 (45.8, 72.4) 98.0 (97.1, 98.8) 0.93 (0.90, 0.96) 
Chloramphenicol 5.9 (4.1, 8.0) 5.5 (3.9, 7.7) 0.25 99.7 (98.8, 100) 97.1 (90.1, 99.7) 99.8 (99.4, 100) 0.99 (0.98, 1.0) 
Ciprofloxacin 8.3 (6.3, 10.8) 7.5 (5.5, 9.9) 0.07 98.9 (97.7, 99.5) 92.8 (85.7, 97.1) 99.4 (98.7, 99.8) 0.98 (0.96, 0.99) 
Clindamycin 12.9 (10.3, 15.8) 10.6 (8.3, 13.3) <0.001* 97.4 (95.8, 98.5) 88.9 (82.6, 93.5) 98.5 (97.6, 99.2) 0.95 (0.92, 0.97) 
Oxacillin 12.9 (10.3, 15.8) 11.4 (9.0, 14.2) <0.001* 98.5 (97.2, 99.3) 94.0 (88.8, 97.2) 99.2 (98.4, 99.6) 0.97 (0.95, 0.99) 
Rifampicin 0.8 (2.6, 1.9) 0.8 (2.6, 18.9) 0.63 99.4 (98.3, 99.8) 60.0 (26.2, 87.8) 99.7 (99.2, 99.9) 0.99 (0.97, 1.0) 
Tetracycline 22.0 (18.8, 25.5) 22.8 (19.5, 26.3) 0.29 96.6 (94.8, 97.9) 92.4 (88.6, 95.2) 97.8 (96.7, 98.6) 0.93 (0.90, 0.96) 
* Significant mid-p McNemar’s chi-square test (p<0.05). 
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Supplementary Table 3. Molecular ecology of nine Staphylococcus pseudintermedius isolates identified as phenotypically susceptible to oxacillin 







Phenotypic Resistance† MLST Genotypic resistance 
N13/4/19 0.5 20 CVN, OXA ST539 aac(6')-aph(2''), dfrG, blaZ, mecA 
N13/4/59 0.125 29 CLI, OXA ST498 aac(6')-aph(2''), aadD-like, ant(6)-Ia,aph(3')-III, erm(B)-like, 
erm(C), blaZ, blaZ-like, mecA 
N13/1/616 0.25 19 AMC, CVN, OXA ST547 blaZ, mecA 
N13/1/627 0.5 21 CLI, OXA ST498 ant(6)-Ia,aph(3')-III, erm(B)-like, blaZ, blaZ-like, mecA 
Q13/1/200 0.25 23 TET Unknown ST ant(6)-Ia,aph(3')-III, tet(M), blaZ, mecA 
V13/2/299 1.0 19 TET ST71 aac(6')-aph(2''), ant(6)-Ia, aph(3')-III, erm(B)-like, dfrG, blaZ, 
mecA 
V13/2/63 0.5 20 TET Unknown ST tet(M)-like, blaZ-like, mecA 
V13/2/16 0.5 19 OXA ST544 blaZ-like, mecA 
W13/1/4 0.5 20 CHL, CIP, CLI, OXA, TET ST45 aac(6')-aph(2''), ant(6)-Ia, aph(3')-III-like, erm(B), dfrG, tet(M), 
catpC221-like, blaZ, mecA-like 
† Phenotypic resistance is based on Clinical and Laboratory Standards Institute interpretation criteria for disc diffusion and broth microdilution. An isolate underwent whole-





Supplementary figure 1. Amoxicillin-clavulanic acid - performance of disc diffusion 
relative to broth microdilution for clinical Staphylococcus pseudintermedius isolates from 
animals (i) distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC 
(µg/ml, depicted on log2 scale), and (iii) two-graph ROC plot. 
 
 
Supplementary figure 2. Cephalothin - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 
depicted on log2 scale), and (iii) two-graph ROC plot. 
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Supplementary figure 3. Chloramphenicol - performance of disc diffusion relative to 
broth microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 
depicted on log2 scale), and (iii) two-graph ROC plot. 
 
 
Supplementary figure 4. Ciprofloxacin - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 
depicted on log2 scale), and (iii) two-graph ROC plot. 
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Supplementary figure 5. Clindamycin - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 
depicted on log2 scale), and (iii) two-graph ROC plot. 
 
 
Supplementary figure 6. Cefovecin - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 
depicted on log2 scale), and (iii) two-graph ROC plot.  
 
 
Supplementary figure 7. Cefoxitin - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 




Supplementary figure 8. Oxacillin - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 
depicted on log2 scale), and (iii) two-graph ROC plot.  
 
 
Supplementary figure 9. Rifampicin - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 




Supplementary figure 10. Tetracycline - performance of disc diffusion relative to broth 
microdilution for clinical Staphylococcus pseudintermedius isolates from animals (i) 
distribution of zone diameter results (ii) scatterplot of zone diameter (mm) and MIC (µg/ml, 











Supplementary material from Chapter 4: 
Intra- and inter-laboratory agreement of the disc diffusion assay for assessing 
antimicrobial susceptibility of porcine Escherichia coli 
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Supplementary Table 1. Identification of twenty porcine Escherichia coli isolates included in 
an intra- and inter-laboratory agreement study evaluating the performance of the disc diffusion 
assay in veterinary laboratories. 
Isolate identification 






















20 ATCC 25922 
a Antimicrobial Resistance and Infectious Diseases Laboratory, Murdoch University 
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Supplementary Table 2. Descriptive statistics for an intra- and inter-laboratory evaluation of the disc diffusion assay by seven laboratories. Five 
zone diameter measurements for six antimicrobial agents on 20 Escherichia coli isolates was reported by each laboratory on five occasions, 
representing 35 zone diameter measurements per isolate/ antimicrobial combination. 
 Mean/ median/ standard deviation/ minimum-maximum 
Isolate Ampicillin Ceftiofur Chloramphenicol Gentamicin Tetracycline Trimethoprim-sulpha 
1 16.6/ 20/ 2.2/ 10-22 26.4/ 26/ 1.7/ 24-30 25.7/ 26/ 1.3/21-28 20/ 20/ 2.0/ 17-29 6.1/ 6/ 0.3/ 6-7 28.2/ 28/ 1.7/ 26-33 
2 6.4/ 6/ 2.4/ 6-20 26.4/ 26/ 2.3/ 21-32 6.4/ 6/ 1.7/ 6-15 12.4/ 12/ 3.2/ 6-24 6.1/ 6/ 0.5/ 6-8 6/ 6/ 0/ 6-6 
3 6.3/ 6/ 1.9/ 6-17 25.7/ 26/ 1.9/ 22-30 6.6/ 6/ 3.2/ 6-25 9.1/ 9/ 3.4/ 6-22 6/ 6/ 0/ 6-6 7.0/ 6/ 4.3/ 6-28 
4 6/ 6/ 0/ 6-6 26.3/ 27/ 3.1/ 10-30 6.1/ 6/ 0.5/ 6-9 8.3/ 8/ 1.3/ 6-10 6/ 6/ 0/ 6-6 6/ 6/ 0/ 6-6 
5 16.9/ 18/ 3.1/ 6-22 25.8/ 26/ 1.7/ 20-30 25.7/ 26/ 1.7/ 23-30 20.7/ 21/ 1.3/ 18-23 6.0/ 6/ 0.2/ 6-7 16.7/ 18/ 4.1/ 6-21 
6 14.7/ 15/ 2.7/ 6-18 24.9/ 25/ 2.2/ 16-29 21.5/ 22/ 3.5/ 6-25 19.5/ 19/ 1.9/ 15-26 21.3/ 22/ 3.3/ 6-25 25.8/ 26/ 4.0/ 6-31 
7 6/ 6/ 0/ 6-6 27.5/ 28/ 3.0/ 15-32 7.1/ 7/ 1.0/ 6-9 10.5/ 10/ 1.5/ 6-14 6.3/ 6/ 0.6/ 6-8 6/ 6/ 0/ 6-6 
8 6/ 6/ 0/ 6-6 25.9/ 26/ 2.2/ 22-33 18.7/ 19/ 2.7/ 6-23 9/ 9/ 1.3/ 6-11 6.1/ 6/ 0.2/ 6-7 6/ 6/ 0/ 6-6 
9 16.9/ 17/ 2.1/ 12-24 26.0/ 26/ 2.7/ 20-30 25.2/ 25/ 1.9/ 20-29 21.0/ 21/1.6/ 17-24 8.3/ 8/ 2.8/ 6-22 28.1/ 28/ 1.9/ 24-32 
10 6.3/ 6/ 1.5/ 6-15 25.6/ 25/ 1.6/ 22-29 22.8/ 24/ 3.2/ 8-27 19.9/ 20/ 2.7/ 10-28 6.4/ 6/ 2.5/ 6-21 27.6/ 28 4.1/ 6-32 
11 6/ 6/ 0/ 6-6 24.9/ 25/ 1.5/ 22-29 23.8/ 24/ 2.3/ 20-31 21.1/ 21/ 1.7/ 18-26 21.8/ 22/ 1.8/ 17-25 23.7/ 24/ 2.1/ 20-29 
12 16.3/ 17/ 2.4/ 6-18 25.4/ 26/ 1.7/ 20-28 8/ 8/ 1.4/ 6-10 11.6/ 12/ 2.1/ 6-21 21.5/ 22/ 2.4/ 15-25 6/ 6/ 0/ 6-6 
13 18.5/ 19/ 2.0/ 10-21 27.1/ 27/ 1.6/ 24-30 6.1/ 6/ 0.6/ 6-9 19.8/ 20/ 1.0/ 18-22 6/ 6/ 0/ 6-6 6/ 6/ 0/ 6-6 
14 6.5/ 6/ 1.5/ 6-13 22.3/ 22/ 2.3/ 18-28 6.2/ 6/ 0.6/ 6-8 21.8/ 21/ 3.0/ 8-26 6.5/ 6/ 0.7/ 6-8 18.3/ 19/ 3.0/ 6-22 
15 6/ 6/ 0/ 6-6 26.9/ 27/ 1.5/ 24-30 8.5/ 8/ 2.6/ 6-21 19.2/ 20/ 2.4/ 11-22 22.8/ 24/ 4.5/ 6-28 6/ 6/ 0/ 6-6 
16 6.0/ 6/ 0.2/ 6-7 28.8/ 29/ 2.7/ 23-33 22.8/ 23/ 2.3/ 17-27 8.1/ 8/ 1.2/ 6-10 23.3/ 23/ 1.9/ 19-27 6.0 /6/ 0.2/ 6-7 
17 6/ 6/ 0/ 6-6 15.9/ 16/ 1.7/ 12-19 23.8/ 24/ 2.2/ 17-28 16.6/ 16/ 1.2/ 13-19 7.0/ 7/ 1.1/ 6-9 8.8/ 6/ 5.7/ 6-25 
18 6/ 6/ 0/ 6-6 11.4/ 11/ 2.9/ 6-25 6/ 6/ 0/ 6-6 10.5/ 11/ 1.6/ 6-13 6.1/ 6/ 0.2/ 6-7 6/ 6/ 0/ 6-6 
19 6.8/ 6/ 2.7/ 6-17 15.5/ 15/ 3.4/ 9-26 7.4/ 6/ 4.7/ 6-25 21.7/ 22/ 2.1/ 18-26 7.3/ 6/ 4.4/ 6-23 7.7/ 6/ 5.6/ 6-28 
20 15.2/ 15/ 2.9/ 6-24 24.8/ 25/ 1.4/ 22-28 22.8/ 23/ 2.2/ 18-27 19.9/ 20/ 1.8/ 16-26 22.7/ 23/ 2.1/ 18-26 26.8/ 27/ 1.3/ 24-29 
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Supplementary Table 3. Performance of the disc diffusion assay from an inter- and intra-laboratory agreement study of seven veterinary 
laboratories where each laboratory assessed the susceptibility of 20 porcine Escherichia coli isolates to six antimicrobials on five occasions. 
EUCAST epidemiologic cut-off values (ECOFF) were used to categorise zone diameter values. Discordance occurred when an individual zone 
diameter disagreed with the median zone diameter for an isolate/ antimicrobial combination. ZD, zone diameter. 
Antimicrobial Total no. of isolate/ 
antimicrobial combinations 
No. of reported wild type 
replicates 
No. of reported non 
wild-type replicates 
No. of major 
errorsb 
No. of very 
major errorsb 
Ampicillin* 700 213 487 13 (6.10%) 5 (1.03%) 
Ceftiofur† NA NA NA NA NA 
Chloramphenicol* 700 348 358 13 (3.74%) 5 (1.40%) 
Gentamicin† 700 399 301 26 (6.52%) 5 (1.67%) 
Tetracycline* 700 211 489 4 (1.90%) 5 (1.02%) 
Trimethoprim-Sulfamethoxazole* NA NA NA NA NA 
Total disagreement 2800 1171 1635 56 (4.78%) 20 (1.22%) 
b Error rates are reported according to ISO 20776–2. Very major error rate is the number of false susceptible results divided by the number of isolates determined to be resistant 
(non-wildtype); Major error rate is the number of false resistant results divided by the number of isolates determined susceptible (wild-type). 
NA, no published EUCAST epidemiologic cut-off value. 
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Supplementary Table 4. Within-subject values of coefficient of variation in the corrected zone diameter measurements (i.e. measurements <6mm 
were corrected to 6mm) for an inter- and intra-laboratory agreement study evaluating the disc diffusion assay within seven veterinary laboratories 
where each laboratory assessed the susceptibility of 20 porcine Escherichia coli isolates to six antimicrobials on five occasions. 
 Coefficient of variance (%) with 95% CIa 
Isolate Ampicillin Ceftiofur Chloramphenicol Gentamicin Tetracycline Trimethoprim-Sulfa 
1 11.2 (6.1, 18.5) 6.3 (5.1, 7.4) 5.2 (3.6, 7.2) 9.9 (5.1, 15.5) 5.3 (3.9, 7.3) 6.0 (4.5, 7.6) 
2 37.0 (0, 48.5) 8.8 (6.6, 11.2) 25.7 (6.6, 11.2) 25.7 (14.0, 35.3) 7.7 (0, 11.3) 0.0 (0, 0) 
3 30.0 (0, 39.1) 7.3 (5.8, 9.1) 48.8 (0, 74.1) 36.9 (15.1, 49.3) 0.0 (0, 0) 61.9 (0, 93.4) 
4 0.0 (0, 0) 12.1 (4.5, 22.3) 8.3 (0, 17.6) 15.9 (13.0, 19.3) 0.0 (0, 0) 0.0 (0, 0) 
5 18.6 (0.5, 28.3) 6.8 (4.7, 9.6) 6.6 (5.0, 8.4) 6.5 (5.5, 7.6) 2.8 (0, 3.9) 24.3 (18.8, 34.1) 
6 18.3 (11.6, 26.7) 9.0 (5.1, 13.6) 16.5 (9.3, 27.2) 9.9 (6.9, 13.8) 15.4 (7.5, 27.1) 15.6 (6.6, 28.5) 
7 0.0 (0, 0) 10.8 (6.3, 17.4) 14.2 (12.5, 16.1) 14.8 (10.9, 19.6) 10.1 (6.8, 12.4) 0.0 (0, 0) 
8 0.0 (0, 0) 8.6 (6.2, 11.4) 14.7 (7.5, 25.7)  14.8 (11.0, 19.6) 3.9 (0, 5.3) 0.0 (0, 0) 
9 12.6 (8.6, 17.4) 10.4 (6.0, 15.2) 7.4 (5.8, 9.6) 7.6 (6.0, 9.5) 33.0 (15.4, 49.6) 6.8 (5.4, 8.4) 
10 24.3 (0, 32.5) 6.1 (5.0, 7.6) 14.0 (7.0, 24.6) 13.8 (8.3, 20.5) 39.4 (0, 65.4) 14.7 (46, 22.9) 
11 0.0 (0, 0) 6.0 (4.3, 7.7) 9.7 (7.3, 12.5) 8.0 (6.1, 10.3) 8.2 (6.3, 10.6) 9.0 (7.0, 11.4) 
12 14.7 (6.3, 25.9) 6.6 (4.8, 8.9) 17.9 (15.1, 20.9) 17.9 (7.7, 28.7) 11.1 (8.6, 14.2) 0.0 (0, 0) 
13 10.6 (5.9, 16.9) 5.8 (4.6, 6.9) 9.0 (0, 13.8) 5.1 (4.1, 6.3) 0.0 (0, 0) 0.0 (0, 0) 
14 23.4 (8.7, 33.1) 10.1 (7.8, 13.1) 9.2 (0, 12.1) 14.4 (8.4, 23.5) 11.5 (8.8, 13.5) 16.5 (6.5, 26.5) 
15 0.0 (0, 0) 5.5 (4.4, 6.7) 30.1 (14.9, 44.8) 12.7 (7.1, 18.4) 19.8 (6.4, 31.1) 0.0 (0, 0) 
16 2.8 (0, 3.9) 9.4 (7.0, 11.7) 10.0 (7.1, 12.9) 14.7 (11.7, 17.9) 8.11 (6.4, 9.8) 2.8 (0, 3.9) 
17 0.0 (0, 0) 10.9 (9.0, 13.4) 9.2 (6.5, 12.3) 7.1 (5.0, 9.5) 15.4 (13.2, 17.6) 65.5 (58.3, 73.1) 
18 0.0 (0, 0) 25.4 (11.1, 38.6) 0.0 (0, 0) 15.4 (10.1, 21.0) 3.9 (0, 5.3) 0.0 (0, 0) 
19 40.0 (0, 50.1) 21.7 14.1, 28.8) 63.5 (34.5, 75.5) 9.6 (8.0, 11.4) 59.8 (37.0, 70.3) 73.0 (0, 82.4) 
20 19.0 (11.4, 27.3) 5.8 (4.6, 7.3) 9.5 (7.5, 11.6) 9.3 (6.6, 12.3) 9.2 (7.7, 11.2) 4.7 (3.8, 5.8) 
Median CV 11.6 8.8 9.9 11.3 10.2 5.8 
NA, not available. 





Supplementary Figure 1. Variation in repeated zone diameter measurements for ampicillin 
(AMP) for a panel of 20 porcine Escherichia coli isolates for an intra- and inter-laboratory 
agreement study assessing the disc diffusion assay. One plot is provided per isolate/ 
antimicrobial combination and represents five repeated measurements for each of 7 laboratories 
(A-G). Horizontal dashed lines represent Clinical and Laboratory Standards Institute (CLSI) 
susceptible and resistant clinical breakpoints relevant to each antimicrobial. 
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Supplementary Figure 2. Variation in repeated zone diameter measurements for ceftiofur 
(CFT) for a panel of 20 porcine Escherichia coli isolates for an intra- and inter-laboratory 
agreement study assessing the disc diffusion assay. One plot is provided per isolate/ 
antimicrobial combination and represents five repeated measurements for each of 7 laboratories 
(A-G). Horizontal dashed lines represent Clinical and Laboratory Standards Institute (CLSI) 
susceptible and resistant clinical breakpoints relevant to each antimicrobial. 
138 
 
Supplementary Figure 3. Variation in repeated zone diameter measurements for 
chloramphenicol (CHL) for a panel of 20 porcine Escherichia coli isolates for an intra- and 
inter-laboratory agreement study assessing the disc diffusion assay. One plot is provided per 
isolate/ antimicrobial combination and represents five repeated measurements for each of 7 
laboratories (A-G). Horizontal dashed lines represent Clinical and Laboratory Standards 
Institute (CLSI) susceptible and resistant clinical breakpoints relevant to each antimicrobial. 
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Supplementary Figure 4. Variation in repeated zone diameter measurements for gentamicin 
(GEN) for a panel of 20 porcine Escherichia coli isolates for an intra- and inter-laboratory 
agreement study assessing the disc diffusion assay. One plot is provided per isolate/ 
antimicrobial combination and represents five repeated measurements for each of 7 laboratories 
(A-G). Horizontal dashed lines represent Clinical and Laboratory Standards Institute (CLSI) 
susceptible and resistant clinical breakpoints relevant to each antimicrobial. 
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Supplementary Figure 5. Variation in repeated zone diameter measurements for tetracycline 
(TET) for a panel of 20 porcine Escherichia coli isolates for an intra- and inter-laboratory 
agreement study assessing the disc diffusion assay. One plot is provided per isolate/ 
antimicrobial combination and represents five repeated measurements for each of 7 laboratories 
(A-G). Horizontal dashed lines represent Clinical and Laboratory Standards Institute (CLSI) 
susceptible and resistant clinical breakpoints relevant to each antimicrobial. 
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Supplementary Figure 6. Variation in repeated zone diameter measurements for 
trimethoprim-sulfamethoxazole (SXT) for a panel of 20 porcine Escherichia coli isolates for an 
intra- and inter-laboratory agreement study assessing the disc diffusion assay. One plot is 
provided per isolate/ antimicrobial combination and represents five repeated measurements for 
each of 7 laboratories (A-G). Horizontal dashed lines represent Clinical and Laboratory 
Standards Institute (CLSI) susceptible and resistant clinical breakpoints relevant to each 










Supplementary material from Chapter 5: 




Beef Feedlot Questionnaire  
Enter confidentiality code here ____________________ 
PART 1: GENERAL BACKGROUND INFORMATION 
 
Select the feedlot size category that best describes your business 
 < 3,000 animals 
 3,000-10,000 animals 
 > 10,000 animals 
 Unanswered 
 
In the past 12 months, how many animals in total were sold from this feedlot? 
 < 10,000 
 10,000 - 20,000 
 20,000-30,000 




In the past 12 months, what is the average time an animal will spend in the feedlot? 
 <80 days 
 80-150 days 
 > 150 days 
 unanswered 
 
In the past 12 months, what percentage of total animals in the feedlot were 'pulled' for treatment? 
 




Have you used tylosin by injection (trade names Bilosin, Tylan, Tylopharm) in the past 12 months? 
 Yes 
 No 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
 
What percentage of 'pulled' animals were given injectable tylosin in the past 12 months? 
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Nominate the purpose/s of using injectable tylosin (individual treatment, mass treatment response, timed or 
scheduled treatment) and the disease syndromes treated 
 Individual mass treatment 
timed/ scheduled 
treatment 
Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, 
foot abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink 
eye) 
❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, 
castration) 
❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
In-feed tylosin 
Have you used in-feed tylosin (trade names Tylan, Tyleco) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed tylosin in the past 12 months?  
 
Select the reason/s in-feed tylosin was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 
❑ don't know 
❑ unanswered 
 
For the past 12 months, select the disease syndromes in-feed tylosin was for – 
(1) mass treatment, and/or  








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
Tilmicosin 
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Have you used tilmicosin by injection (trade names Micotil, Tilmax) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable tilmicosin in the past 12 months? 
 
Nominate the purpose/s of using injectable tilmicosin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, 
castration) 
❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
In-feed tilmicosin 
Have you used in-feed tilmicosin (trade names Micotil, Tilmax) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed tilmicosin in the past 12 months? 
 
Select the reason/s in-feed tilmicosin was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 




For the past 12 months, select the disease syndromes in-feed tilmicosin was used for – 
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, 
castration) 
❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Injectable erythromycin 
Have you used erythromycin by injection (trade names Erymicin, Gallimycin) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable erythromycin in the past 12 months? 
 
Nominate the purpose/s of using injectable erythromycin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, 
castration) 
❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  




Have you used tulathromycin by injection (trade name Draxxin) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable tulathromycin in the past 12 months? 
 
Nominate the purpose/s of using injectable tulathromycin (individual treatment, mass treatment response, timed 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, 
castration) 
❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Short-acting oxytetracycline 
Have you used short-acting oxytetracycline by injection (trade names Alamycin, Engemycin, Terramycin 100, 
Tetravet 10) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable short-acting oxytetracycline in the past 12 months? 
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Nominate the purpose/s of using injectable short-acting oxytetracycline (individual treatment, mass treatment 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, 
castration) 
❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Long-acting oxytetracycline 
Have you used long-acting oxytetracycline by injection (trade names Alamycin LA, Bicatop LA, Hexazol LA, 
Oxytet 200 LA, Terramycin/LA, Tetravet 200 LA) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable long-acting oxytetracycline in the past 12 months? 
 
Nominate the purpose/s of using injectable long-acting oxytetracycline (individual treatment, mass treatment 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  







In-feed oxytetracycline or chlortetracycline 
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Have you used in-feed oxytetracycline or chlortetracycline (trade names CTC200, Oxy-Eco 100, Tetravet 980, 
Terramycin 200, Terramycin 880) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed oxytetracycline or chlortetracycline in the past 12 months? 
 
Select the reason/s in-feed oxytetracycline or chlortetracycline was used in the past 12 months (select multiple 
options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 
❑ don't know 
❑ unanswered 
 
For the past 12 months, select the disease syndromes in-feed oxytetracycline or chlortetracycline was used for  
(1) mass treatment and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Short-acting ceftiofur 
Have you used short-acting ceftiofur by injection (trade names Calefur, Excenel, Norocef) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
 
What percentage of 'pulled' animals were given injectable short-acting ceftiofur in the past 12 months? 
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Nominate the purpose/s of using injectable short-acting ceftiofur (individual treatment, mass treatment response, 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Long-acting ceftiofur 
Have you used long-acting ceftiofur by injection (trade names Excede) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable long-acting ceftiofur in the past 12 months? 
 
Nominate the purpose/s of using injectable long-acting ceftiofur (individual treatment, mass treatment response, 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Florfenicol 
Have you used florfenicol by injection (trade names Nuflor) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
151 
What percentage of ‘pulled’ animals were given injectable florfenicol in the past 12 months? 
 
Nominate the purpose/s of using injectable florfenicol (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Short-acting penicillin 
Have you used short-acting penicillin by injection (trade names Depocillin, Norocillin SA, Penethaject, 
Propercillin) in the past 12 months? 
 yes 
 no 
 don’t know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of ‘pulled’ animals were given injectable short-acting penicillin in the past 12 months? 
 
Nominate the purpose/s of using injectable short-acting penicillin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  









 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable long-acting penicillin in the past 12 months? 
 
Nominate the purpose/s of using long-acting penicillin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  








Have you used amoxicillin by injection (trade names Betamox, Bimoxyl, Bomox, Moxylan) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable amoxicillin in the past 12 months?  
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Nominate the purpose/s of using injectable amoxicillin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Trimethoprim and/or sulphonamides 
Have you used trimethoprim and/or sulphonamides by injection (trade names Amphoprim, SD333 Sulfadimidine, 
TMPS 240, Tribactral, Triprim, Trisoprim 480, Trivetrin) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable trimethoprim/ sulphonamides in the past 12 months?  
 
Nominate the purpose/s of using injectable trimethoprim/ sulphonamides (individual treatment, mass treatment 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
In-feed trimethoprim and/or sulphonamides 
Have you used in-feed trimethoprim and/or sulphonamides (trade names Sulphatrim, Sulprim, Trimidine) in the 
past 12 months? 
 yes 
 no 




IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed trimethoprim/ sulphonamides in the past 12 months?  
 
Select the reason/s in-feed trimethoprim/ sulphonamides were used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 
❑ don't know 
❑ unanswered 
 
For the past 12 months, select the disease syndromes in-feed trimethoprim/ sulphonamides was used for – 
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
Neomycin 




 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable neomycin in the past 12 months? 
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Nominate the purpose/s of using injectable neomycin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Gentamicin 
Have you used gentamicin by injection (trade names Gentam, Gentamax) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of 'pulled' animals were given injectable gentamicin in the past 12 months? 
 
Nominate the purpose/s of using injectable gentamicin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
Enrofloxacin 
Have you used enrofloxacin by injection (trade names Baytril, Enrotril) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
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What percentage of 'pulled' animals were given injectable enrofloxacin in the past 12 months?  
 
Nominate the purpose/s of using injectable enrofloxacin (individual treatment, mass treatment response, timed or 






Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
In-feed virginiamycin 
Have you used in-feed virginiamycin (trade name Eskalin) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
 
What percentage of lots were given in-feed virginiamycin in the past 12 months?  
 
Select the reason/s in-feed virginiamycin was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 




For the past 12 months, select the disease syndromes in-feed virginiamycin was used for –  
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
In-feed monensin 




 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed monensin in the past 12 months? 
 
 
Select the reason/s in-feed monensin was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 




For the past 12 months, select the disease syndromes in-feed monensin was used for –  
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
In-feed salinomycin 
Have you used in-feed salinomycin (trade name Posistac, Saleco) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed salinomycin in the past 12 months?  
 
Select the reason/s in-feed salinomycin was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 
❑ don't know 
❑ unanswered 
 
For the past 12 months, select the disease syndromes in-feed salinomycin was used for –  
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  




Have you used in-feed lasalocid (trade name Bovatec) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed lasalocid in the past 12 months?  
 
Select the reason/s in-feed lasolacid was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 
❑ don't know 
❑ unanswered 
 
For the past 12 months, select the disease syndromes in-feed lasolacid was used for –  
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
In-feed narasin 
Have you used in-feed narasin (trade name Maxiban, Monteban) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
What percentage of lots were given in-feed narasin in the past 12 months?  
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Select the reason/s in-feed narasin was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 
❑ don't know 
❑ unanswered 
 
For the past 12 months, select the disease syndromes in-feed narasin was used for –  
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot abscess, 
lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
In-feed flavophospholipol 
Have you used in-feed flavophospholipol (trade name Flaveco) in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
IF ANSWERED YES PROCEED TO NEXT QUESTION. IF ANSWERED ‘NO’, ‘DON’T KNOW’ OR 
‘UNANSWERED’ SKIP TO NEXT ANTIMICROBIAL AGENT 
 
What percentage of lots were given in-feed flavophospolipol in the past 12 months?  
 
Select the reason/s in-feed flavophospholipol was used in the past 12 months (select multiple options) 
❑ mass treatment in response to a disease outbreak (metaphylaxis) 
❑ timed/ scheduled treatment of lots (prophylaxis) 
❑ prevention 
❑ growth promotion 




For the past 12 months, select the disease syndromes in-feed flavophospholipol was used for –  
(1) mass treatment, and/or 








Respiratory (e.g. laryngitis, pneumonia) ❑  ❑  ❑  
Gut (e.g. acidosis, blood scours, scours, rumen health) ❑  ❑  ❑  
Musculoskeletal (lameness, footrot, swollen joints/ legs, foot 
abscess, lumpy jaw, wooden tongue) 
❑  ❑  ❑  
neurological (e.g. PEM/TEME, dropped ear, circling, pink eye) ❑  ❑  ❑  
Urogenital (e.g. prolapsed prepuce, calving, waterbelly, castration) ❑  ❑  ❑  
Other (e.g. tick fever, honker) ❑  ❑  ❑  
Specify other:  
 
PART 3: VETERINARY TREATMENT CONTROLS 
How often does a registered veterinarian visit the feedlot? 
 never 
 once a year 
 twice a year 
 four times a year 
 monthly 
 more than once a month 
 unanswered 
 




 don't know 
 unanswered 
 
Has a veterinarian issued the feedlot with a treatment protocol/ schedule or 'prescribed veterinary medicine and 
veterinary chemical list' in the past 12 months? 
 yes 
 no 
 don't know 
 unanswered 
 
Is the treatment protocol/ 'prescribed list' followed by feedlot staff? (select the most appropriate option) 
 always (100% of the time) 
 frequently (approx 80% of the time) 
 often (approx 60% of the time) 
 occasionally (approx 40% of the time) 





Are sick animals assessed for their response to treatments before they are returned to their 'home pen'?  
 yes 
 no 
 don't know 
 unanswered 
 
PART 4: SUPPLY AND USE OF VETERINARY CHEMICALS 
Who supplies veterinary prescription drugs (e.g. S4 chemicals such as antimicrobial agents, anti-inflammatories) 
for use in the feedlot (can select multiple options) 
❑ consulting vet 
❑ other vet 
❑ online 
❑ don't know 
❑ unanswered 
 
Where do you buy animal health products such as drenches and pesticides (i.e. over-the-counter products) for use 
in the feedlot? (can select multiple options) 
❑ vet 
❑ online 
❑ rural merchandise store 
❑ other ____________________ 
❑ don't know 
❑ unanswered 
 
Who has access to veterinary prescription drugs at the feedlot? (can select multiple options)  
❑ animal health crew/ stock handlers 
❑ feeding crew/ maintenance crew 
❑ management 
❑ Other ____________________ 
❑ don't know 
❑ unanswered 
 
Who can access animal health products such as drenches and pesticides at the feedlot? (can select multiple options) 
❑ animal health crew/ stock handlers 
❑ feeding crew/ maintenance crew 
❑ management 
❑ Other ____________________ 
❑ don't know 
❑ unanswered 
 
Who can administer veterinary prescription drugs to animals at the feedlot? (can select multiple options)  
❑ animal health crew/ stock handlers 
❑ feeding crew/ maintenance crew 
❑ management 
❑ Other ____________________ 




Who administers animal health products (drenches, pesticides) to animals at the feedlot? (can select multiple 
options) 
❑ animal health crew/ stock handlers 
❑ feeding crew/ maintenance crew 
❑ management 
❑ Other ____________________ 
❑ don't know 
❑ unanswered 
 
How do you identify animals that have been treated with a prescription drug (with an applicable withholding 
period)? (select one option) 
 hospital tag only 
 management computer software only 
 hospital tag AND management computer software 
 do not identify treated animals 
 other ____________________ 
 don't know 
 unanswered 
 
What training is provided to staff who administer veterinary prescription drugs (e.g. antimicrobial agents, anti-
inflammatories) to animals? (can select multiple options) 
❑ staff trained by the feedlot veterinarian 
❑ staff trained by the livestock supervisor 
❑ off-site courses, seminars such as ChemCert 
❑ other ____________________ 
❑ don't know 
❑ unanswered 
 
PART 5: STORAGE AND CHEMICAL STOCK CONTROL 
Is the main storage area for veterinary prescription drugs locked at all times? 
 yes 
 no 
 don't know 
 unanswered 
 
Are veterinary prescription drugs and animal health products stored according to the label directions e.g. if the 
drug requires refrigeration is it always kept refrigerated? 
 yes 
 no 
 don't know 
 unanswered 
 
How is veterinary chemical (i.e. prescription and over-the-counter) inventory managed for incoming/ outgoing 
chemicals? (select one option) 
 computerised records 
 manual entry - record book 
 no records 
 other ____________________ 




How often are veterinary chemical stocks audited? (select one option) 
 never 
 once a year 
 twice a year 
 four times a year 
 monthly 
 more than monthly 
 unanswered 
 
How are out-of-date veterinary chemicals managed? (select one option) 
 immediate disposal 
 vet approved short extension of shelf life 
 used until complete 
 other ____________________ 













Antimicrobial agent Use Risk Matrix: weightings and justifications 
 
 
Antimicrobial agent Use Risk Matrix – Beef Feedlots 














High risk (4-5) High High Extreme Extreme Extreme VL: very low antimicrobial agent use risk 
Medium risk (3-4) Medium Medium High High High L: low antimicrobial agent use risk 
Some risk (2-3) Medium Medium Medium Medium High M: moderate antimicrobial agent use risk 
Low risk (1-2) Low Low Medium Medium Medium H: high antimicrobial agent use risk 
Negligible risk (0-1) Low Low Low Low Low E: extreme antimicrobial agent use risk 
 
Behaviour ratings Optimal Adequate Suboptimal Inadequate Non-compliant 
Vet issued treatment protocol Yes Yes Yes Yes or No No 
Tx protocol instructions followed Always Mostly Mostly Not always No 
Animal weighed prior to treatment Always Always No/ Not always No/ Not always No 
Correct AB use – dose, route, duration Always Always Always/ Mostly No Unknown 
Tx recorded and WHP observed Always Always Always/ Mostly No No 
Likely overall score 0-1 1-2 3-4 4-5 5 
 
Antimicrobial agent Use ratings Negligible risk Low risk Some risk Medium risk High risk 
Antimicrobial agent index:      
Estimated proportion population administered drug in previous 12months 0% <2% 2-10% 10-20% >20% 
Importance weighting – unrated, low, med, high imp drug Nil Low Low, Med, +/- high Low - high Low - high 










Overall antimicrobial agent index:      
Sum of all individual antimicrobial agent indices (positive values) 0 <10 10-40 40-70 >70 
Likely overall score 0 1-2 2-3 3-4 4-5 
 
Antimicrobial agent Use Risk Matrix 
Purpose: 
• Categorise the risk of antimicrobial use practices at the individual feedlot level. 
• A communication tool for industry stakeholders to understand feedlot level risk profiles 
based on antimicrobial use practices 
• Can be used to assist antimicrobial stewardship adoption in beef feedlot sector 
• The matrix and risk index have a flexible format so they can be changed to reflect the 
changing risk profile of any of the factors included in the index as more data comes to 
hand (e.g. importance weightings applied to drugs). 
 
Determination of antimicrobial agent use behaviour ratings 
Based on the approach to assessing quality of antimicrobial use presented in Antimicrobial 





• Treatment protocol is in place and is always followed. 
• Bodyweight is measured. 
• Indication is recorded 
• Correct antimicrobial agent is used, dosage, route, duration and WHP is followed 
Adequate 
• Treatment protocol is in place but is not always followed. 
• Bodyweight is measured 
• Indication is recorded 
• Correct antimicrobial agent is used, dosage, route, duration and WHP is followed 
INAPPROPRIATE 
Suboptimal 
• Treatment protocol is in place and is followed. 
• Bodyweight is not measured. AND/OR 
• Indication is not recorded. 
• Correct antimicrobial agent is used, dosage, route, duration and WHP is followed 
Inadequate 
• Treatment protocol is in place but is not always followed. AND/OR 
• Indication is not recorded. AND/OR 
• Bodyweight is not measured. AND/OR 
• Correct antimicrobial agent is not used, dosage, route or duration may not be optimal. 




Treatment protocol is not documented. Bodyweight is not measured. Indication is not 





Determination of antimicrobial agent use ratings 
The antimicrobial agent use ratings are a measure to quantify the amount of antimicrobial agents 
(by injection and in-feed) used by a beef feedlot. It is based on four rankings or weightings: 
1. Importance ranking of antimicrobial agents included in survey 
2. Use of antimicrobial agents in animals in past 12 months 
3. Frequency of antimicrobial agent use (by drug) in past 12 months 
4. Antimicrobial agent treatment by disease syndrome, based on risk to human health 
The index is used to assess the level of antimicrobial agent use in beef feedlot herds and identify 
potential risk factors contributing to high antimicrobial agent use in feedlot conditions. 
 
Calculation of antimicrobial agent use ratings: 
• Individual Drug index = (proportion treated) x (drug) x (route of administration) 
• Herd index = sum of all individual drug indices (range 0 to infinity) 
• See Tables 1 to 4 for categorisation of risk 
 
Weightings applied for antimicrobial agent use ratings: 
Antimicrobial agent class importance weightings: 
• Weightings are based on Australian Strategic and Technical Advisory Group 
(ASTAG) ratings (2018). The higher the ASTAG rating the higher the weighting 
(Tables 1 and 2): 
o 3 = high importance drugs (ceftiofur, enrofloxacin) 
o 2 = medium importance drugs (trim-sulpha) 
o 1 = low importance drugs (tetracyclines, penicillins etc) 
o 0 = unrated drugs (ionophores, glycophospholipids) 
 
Route of administration weightings: 
• Weighting is based on antimicrobial risk to microbiota. The higher the weighting, 
the higher the risk of resistance developing in the microbiota. In-feed 
antimicrobial agents have a higher risk than injectable drugs. In-feed 
antimicrobial agents are usually fed for a long time period and the dose is often 
dependent on voluntary intake of feed. In contrast, injectable drugs are more 
commonly a once-off treatment with a short (or long) duration of action: 
o 2 = in-feed antimicrobials 






Table 1. Importance ranking of antimicrobial agents based Australian Strategic and Technical 
Advisory Group (ASTAG) rankings on risk of AMR to human health 
 
Drug Class ASTAG 
Rating 
AB use index 
rating* 
Ceftiofur – SA, LA 3rd gen cephalosporin High 3.0 
Enrofloxacin Fluoroquinolone High 3.0 
Virginiamycin Streptogramin High 3.0 
Trim-sulfa Sulphonamides, DHFR inhibitors Medium 2.0 
Gentamicin Aminoglycoside Medium 2.0 
Neomycin Aminoglycoside Low 2.0 
Tylosin, Tilmicosin, Erythromycin, 
Tulathromycin 
Macrolide Low 2.0 
Florfenicol Amphenicol Low 2.0 
Oxytetracycline – SA, LA Tetracycline Low 1.0 
Penicillin – SA, LA, amoxicillin Penicillin Low 1.0 
Monensin, salinomycin, lasalocid, narasin Ionophore  unrated 0 
Flavophospholipol Glycophospholipid unrated 0 (?) 
* AB use index weighting assigned ASATG rankings and risk of resistance gene transfer from animal bacteria to humans (See 
Table 2). 
 
Table 2: Justification applied to Antimicrobial agent Use index rating according to the risk of 
AMR to human health 
AB use 
ranking 
Category Justification*  
0 Low importance drug, no reported 
resistance 
Not ranked by ASTAG, no reported mechanism of 
resistance in humans or animals 
1 Low importance drug, resistance 
reported 
Transfer of resistance – via human and animal pathways, 
direct human infection 
2 Medium importance drug, 
resistance reported 
Transfer of resistance – via human and animal pathways, 
direct human infection 
3 High importance drug, resistance 
reported 
Transfer of resistance – via human and animal pathways, 
direct human infection 
* Rating is based on ASTAG rankings, and transfer pathways of resistance elements in humans and animals. 
 
Table 3. Use of antimicrobial agents in feedlot cattle in past 12 months 
 
Ranking Definition 
0 Not antimicrobial agent use 
1 Injection antimicrobial agent use only 
2 In-feed antimicrobial agent use only 
3 Injection and in-feed antimicrobial agent use 
 




0 0% No use 
1 0-2% Not much use 
2 2.1-10% Some use 
3 10.1-20% Very much use 
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